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1.1. Introduction 
Obesity is a chronic disorder affecting over a billion adults world-wide. The 
prevalence of obesity will probably have doubled by the year 2030 and it is predicted 
that the obesity epidemic will become a major health problem of the 21st century [1]. 
With the increasing number of patients suffering from obesity, the prevalence of 
complications resulting from the excess of adipose tissue is also growing [2]. 
Overweight and obesity are associated with high morbidity and mortality, particularly 
with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus 
(T2DM) [3-5]. An important common denominator connecting these complications is 
the metabolic syndrome. 
1.2. The metabolic syndrome 
1.2.1. Historic overview  
The metabolic syndrome defines a clustering of risk factors that is driven by obesity 
and the term "metabolic syndrome" dates back to at least the late 1950s, but came into 
common usage in the late 1970s and described various associations of risk factors with 
diabetes that had been noted as early as the 1920s [6, 7]. In 1947 Vague observed that 
upper body obesity appeared to be associated with diabetes and atherosclerosis [8].  
Reaven was the first to implicate insulin resistance as the main mechanism underlying 
the aberrant metabolic changes in the metabolic syndrome [9]. These changes include 
hyperinsulinemia, hypertension, increased plasma triglyceride concentration, and 
decreased high-density lipoprotein (HDL) cholesterol concentration, all of which have 
been shown to be associated with increased risk for CVD as well as T2DM. Since the 
first description of the metabolic syndrome, initially known as the insulin resistance 
syndrome and syndrome X, several clinical definitions have been proposed by 
organisations and study groups (including the World Health Organisation (WHO) 
[10], International Diabetes Federation (IDF) [11], European Group for study of 
Insulin Resistance (EGIR) [12] and American Heart Association – National 
Cholesterol Education Program Adult Treatment Panel III (AHA/NCEP-ATP III) 
[13]). These different definitions generally included similar components but different 
emphasis was laid on individual components and different cut-off values were used. 
Some required presence of specific components like insulin resistance (WHO) or 
abdominal obesity (IDF) while others (EGIR, AHA / NCEP-ATP III) stated that the 
presence of 3 out of 5 components means that a patient has the metabolic syndrome. 
Most of the discussion about the definition of the metabolic syndrome focussed on 
how ‘obesity’ should be defined and whether e.g. insulin resistance and 
microalbuminuria needed to be included. 
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1.2.2. Definition 
The use of different definitions for one and the same syndrome complicated 
comparability of studies and led to confusion. The definitions of the metabolic 
syndrome that have been most widely used are from the IDF and the AHA – national 
heart lung and blood institute (NHLBI). In 2005 they made an attempt to reconcile 
their clinical definitions but some differences still remained [11, 14]. Recently, the IDF 
and AHA/NHLBI re-evaluated their definitions and came to the agreement that 
abdominal obesity should not be a prerequisite for diagnosis but is one of the five 
criteria and agreed on the definition as presented in Table 1.1 [15]. Further evidence is 
still needed to determine definitive sex- and ethnicity-specific cut-off values for waist 
circumference particularly. For this, more longitudinal data on how waist relates to 
risk of CVD and T2DM are needed in different ethnic populations. Different 
thresholds have already been defined for various populations (for example: European 
[16], United states [17], Japanese [18], Chinese [19]). However the question remains 
whether the same criteria should be applied to someone from a particular ethnic 
group, regardless of the country they live in [15]. 
 
Table 1.1: Criteria for Clinical Diagnosis of the metabolic syndrome[15] 
Measure Categorical cut-off value  
Elevated waist circumference Population- and country-specific definitions 
≥ 102 cm in males# 
≥ 88 cm in females# 
Elevated triglycerides ≥ 1.7 mmol/L or 
drug treatment for elevated triglycerides* 
Reduced HDL-cholesterol < 1.03 mmol/L in males 
< 1.3 mmol/L in females or 
drug treatment for reduced HDL-cholesterol* 
Elevated blood pressure ≥ 130 mmHg systolic blood pressure and/or 
≥ 85 mmHg diastolic blood pressure or 
antihypertensive drug treatment in a patient with a history of hypertension 
Elevated fasting glucose ≥ 5.6 mmol/L or 
drug treatment for elevated blood glucose level 
 
*the most commonly used drugs for elevated triglycerides and reduced HDL-cholesterol are fibrates and nicotinic acid, 
subjects taking one of these drugs are presumed to have high triglycerides and/or low HDL-cholesterol; 
#these are the values as defined for populations in Europe [16], United States [17], Canada [20] 
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1.2.3. Prevalence of the metabolic syndrome 
In a conglomerate of studies from Sweden, Spain, Netherlands, Italy, France, England 
and Denmark (in total >15,000 subjects), the prevalence of the metabolic syndrome, 
according to the WHO definition, varied from 13% in non-diabetic male subjects aged 
<40 yrs, up to 33% in non-diabetic male subjects older than 55 years of age. For 
women the prevalence of the metabolic syndrome overall varied from 4% up to 21% 
for the different age-categories [21]. The prevalence of the metabolic syndrome is thus 
highly age-dependent and, as described in paragraph 2.2, varies between different 
ethnic populations. It also depends on which definition is used and whether ethnicity 
specific cut-off values were used. There may be a difference in the prevalence of up to 
18% between the definitions by NCEP-ATP III, IDF, WHO and AHA-NHLBI [22, 
23]. But regardless of the exact definition used, the prevalence of the metabolic 
syndrome is rapidly increasing in developed and in developing countries, worldwide. 
1.2.4. Is the metabolic syndrome a distinct clinical entity? 
There remains debate on the validity of the metabolic syndrome as a distinct entity. It 
has been argued that the metabolic syndrome falls short of the mark as a predictive 
tool for CVD risk since there is conflicting evidence on whether the metabolic 
syndrome provides more information than its components or whether it adds any 
additional risk to the Framingham Risk Score. Some reported that the metabolic 
syndrome was associated with CVD risk even after adjustment for conventional risk 
factors or for the Framingham Risk Score, arguing in favour of its use and relevance 
[24-26] while others found no evidence for the value of the metabolic syndrome 
above its components or existing risk models as a predictive tool for CVD and have 
questioned its utility and recommend against it’s use [27-29]. Since the prevalence of 
(visceral) obesity increased dramatically in the last decades, obesity became important 
for the prediction of CVD. However, it is not included in the Framingham Risk Score 
so reconsideration of the Framingham Risk Score would be needed to investigate 
whether other risk factors like visceral obesity should be included into the score if the 
metabolic syndrome will not be accepted as a global risk scoring algorithm [30, 31]. 
Whatever the uncertainties of the definition and aetiology, the metabolic syndrome is 
a useful measure for early identification of subjects with higher risk of CVD and 
T2DM. 
1.3. Main metabolic disturbances in the metabolic syndrome  
A disturbed adipose tissue metabolism appears to underlie the metabolic syndrome. 
This is in the majority of subjects mainly due to excess accumulation of fat (i.e. in 
obese subjects with the metabolic syndrome) but in a minority of subjects, for 
instance those who are (genetically) predisposed to a disturbed adipose tissue 
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metabolism, it may already be present at lower fat accumulation (i.e. non-obese 
subjects with the metabolic syndrome). Especially visceral adipose tissue has been 
identified as an important component of the metabolic syndrome. Metabolically 
compromised visceral fat lies at the basis of metabolic disturbances in glucose- and 
lipid metabolism as well as hypertension, possibly via induction of a low-grade 
inflammatory response and insulin resistance [30]. However, it is not exactly clear in 
which order these processes occur and several vicious cycles appear to be present 
(Figure 1.1). The question that remains is how visceral abdominal obesity can lead to 
inflammation and insulin resistance which will be discussed below. 
  
 
Figure 1.1: The association of obesity with the components of the metabolic syndrome, insulin resistance, 
inflammation, and endothelial dysfunction which increase the risk of cardiovascular disease and type 2 
diabetes 
1.3.1. Inflammation in the metabolic syndrome 
A majority of the subjects with the metabolic syndrome have moderate to substantial 
abdominal obesity associated with dysregulated visceral adipose tissue metabolism, 
which is in part a consequence of visceral adipose cell enlargement and the associated 
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infiltration of macrophages, leading to adipose-tissue inflammation [30, 32]. Obesity is 
thus associated with an increased production of inflammatory cytokines, which 
particularly but not exclusively originate from visceral adipose tissue. These 
inflammatory cytokines can induce or aggravate insulin resistance in visceral adipose 
tissue, as well as in other tissues including muscle and liver. Even though considerable 
insight has been acquired in the mechanisms by which many inflammatory factors 
mediate insulin resistance, it is still unclear whether inflammation is a primary event 
that links visceral obesity and insulin resistance, or is rather secondary to 
hyperglycaemia or hyperlipidaemia.  
Tumour necrosis factor α (TNFα) is one of the first molecular links between obesity 
and inflammation that was discovered [33, 34]. TNFα activates the intracellular 
IKKβ/NFκB signalling pathway leading to decreased insulin signal transduction via 
the insulin receptor substrate (IRS). The concept of adipose tissue as a site for the 
production of cytokines and other bioactive substances quickly extended beyond 
TNFα to include interleukin 6 (IL6), IL1β, monocyte chemoattractant protein-1 
(MCP-1), plasminogen activator inhibitor-1 (PAI-1), angiotensinogen, serum amyloid 
A (SAA), leptin, resistin, adiponectin and others [35-37]. Many of the pro-
inflammatory cytokines can induce insulin resistance by activating JNK and 
IKKβ/NFκB pathways [38, 39]. Some adipose tissue-derived factors, e.g. adiponectin 
and leptin, are true adipokines in the sense that they are produced exclusively by 
adipocytes, while most of the previously-mentioned cytokines are also expressed in 
activated macrophages and/or other cell types in the adipose tissue [36]. In contrast to 
most adipose-derived factors, adiponectin has anti-inflammatory and anti-atherogenic 
properties [35] and its secretion is reduced in obesity, insulin resistance and T2DM 
[40]. In the liver, pro-inflammatory gene expression (C-reactive protein (CRP) and 
others) also increases with increasing adiposity [41]. This suggests that pro-
inflammatory cytokines secreted by visceral adipose tissue induce an inflammatory 
response in the liver and / or that fat accumulation in the liver, which is a highly 
prevalent finding in the metabolic syndrome (paragraph 1.3.1), induces an 
inflammatory response, similar to that in the visceral adipose tissue [36]. 
The effects of visceral adipose tissue-derived cytokines may be local (paracrine), 
leading to enhanced insulin resistance in visceral adipose tissue, or systemic 
(endocrine), thus inducing insulin resistance and other inflammatory responses in 
other tissues such as muscle and liver. Besides insulin resistance inflammatory 
cytokines may also induce endothelial dysfunction. TNFα and IL6 can lead to 
increased expression of adhesion molecules such as intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) which enhance monocyte 
adhesion to the endothelium. At the same time MCP-1 does not only increase the 
migration of monocytes but also favors its transformation into foam cells [42], which 
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causes endothelial injury, reflected by higher concentrations of von Willebrand factor 
(vWf) in plasma [43]. 
1.3.2. Complement in the metabolic syndrome 
A specific inflammation- and insulin resistance-associated factor with potential 
relevance in the metabolic syndrome is complement C3, the most abundant 
complement protein in the circulation. The complement system is part of the innate 
immune system and can be activated via three pathways; the classical, the lectin and 
the alternative pathway [44, 45]. These three pathways all lead to activation of C3, 
which is mainly produced by the liver but is also expressed by adipose tissue and 
vascular cells [46, 47] and is strongly associated with obesity and insulin resistance [48, 
49] and also with the metabolic syndrome, cardiovascular risk factors and CVD [50, 
51]. 
Complement activation is increasingly recognized as a metabolic regulator in e.g. 
adipose tissue homeostasis and insulin resistance [52]. It can induce (systemic) 
inflammation and may specifically be involved in adipose tissue inflammation and 
insulin resistance [44, 45, 52]. 
1.3.3. Non-esterified fatty acids, non-alcoholic fatty liver disease and 
dyslipidaemia in the metabolic syndrome  
Loss of insulin sensitivity in adipose tissue can lead to an increased release of non-
esterified fatty acids (NEFA) due to decreased inhibition of hormone sensitive lipase 
by insulin [53, 54]. Especially visceral adipose tissue drains into the portal circulation 
and NEFA derived from this particular fat depot will thus be directed towards the 
liver [55, 56], which has several consequences. Firstly, it leads to increased hepatic 
triglyceride synthesis and increased hepatic concentration of intermediates of NEFA / 
triglyceride metabolism (e.g. diacylglycerol) that can induce (or worsen) hepatic insulin 
resistance. Secondly, NEFA stimulate hepatic triglyceride production and this, in 
combination with insufficient elimination of triglycerides from the liver, contributes to 
the development of non-alcoholic fatty liver disease (NAFLD) [53, 54]. The 
combination of hepatic insulin resistance and increased amounts of hepatic 
triglycerides in NAFLD contributes to an increased production and secretion of type 
1 very-low-density lipoproteins (VLDL-1, i.e. the largest and most triglyceride-
enriched VLDL) rather than VLDL-2 [57]. The most important components of 
dyslipidemia in the metabolic syndrome include increased plasma triglycerides levels, 
increased small dense low-density lipoprotein (LDL) cholesterol and decreased levels 
of HDL cholesterol [58]. This particular type of dyslipidaemia is also known as the 
atherogenic lipoprotein profile. This atherogenic lipoprotein profile is particularly 
generated in case of NAFLD, insulin resistance and excess VLDL-1 production. 
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1.4. The metabolic syndrome and cardiovascular disease 
The metabolic syndrome was originally defined as a tool to identify subjects with an 
elevated risk of CVD. The metabolic syndrome is associated with incident and 
prevalent CVD in various studies [59]. Inflammation, insulin resistance, dyslipidaemia 
and complement C3, as described in the previous paragraphs in relation to the 
metabolic syndrome, are all also associated with a higher risk of CVD [51, 60-63].   
Inflammatory cytokines enhance the attachment to and migration of monocytes into 
the vessel wall and their conversion to macrophages [64]. This process is integral to 
the development of atherosclerosis. Macrophages and smooth muscle cells in the 
arterial wall will accumulate cholesterol–rich lipoproteins (LDL and small dense LDL), 
which results in the formation of lipid-laden foam cells and fatty streaks. Ultimately, 
these early lesions will evolve into advanced atherosclerotic plaques. Especially TNFα 
is involved in this process. It activates the transcription factor NF-κB, which 
orchestrates a series of inflammatory changes in the vascular tissue, including 
expression of adhesion molecules, like ICAM-1 and VCAM-1 [65]. The cytokine IL-6 
stimulates hepatic production of CRP, which comprises an important marker of 
vascular inflammation and is a predictor of atherosclerosis [66-68]. 
Insulin resistance leads to generation of the atherogenic lipoprotein profile which can 
in turn accelerate the atherosclerotic process. Firstly, because specific properties of the 
small dense LDL make them even more atherogenic than normal LDL. On the one 
hand because of their size, they penetrate the arterial wall more easily, and on the 
other hand since they are more easily oxidized, small dense LDL forms a better 
substrate for uptake in macrophages. Secondly, because the lower levels of HDL 
concomitantly compromise reverse cholesterol transport. Insulin resistance may also 
lead to hyperinsulinaemia, (relative) β-cell exhaustin and subsequently to 
hyperglycaemia which might additionally accelerate the atherosclerotic process. Several 
mechanisms via which this might occur have been described. One of the mechanisms 
is that non-enzymatic glycosylation of (lipo-)proteins in the arterial wall changes the 
normal function of proteins that might lead to interference with receptor recognition 
and changing enzymatic activity. Another proposed mechanism is the activation of 
protein kinase C (PKC) after exposure to high glucose, resulting in an increase of 
transforming growth factor-β expression. This factor plays an important role in 
regulating extracellular matrix production by activating gene expression of 
proteoglycans and collagen [69]. These describe hyperglycemia-related phenomena 
that may be most relevant in subjects with metabolic syndrome-associated T2DM, 
rather than in the metabolic syndrome in general.  
Of note, CVD has various aspects with different aetiology including among others 
coronary heart disease (CHD) and peripheral arterial disease (PAD). CHD occurs in 
the coronary vascular bed while PAD and stroke occur in the peripheral and cerebral 
vascular bed, respectively. CHD is the most frequent vascular disease associated with 
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the metabolic syndrome and occurs when the elastic smooth vessel wall of coronary 
arteries develop plaques, including fatty deposits and inflammatory cells. This leads to 
obstruction of the arteries causing ischaemia. The plaques might eventually rupture 
which causes total occlusion of the coronary artery and acute coronary artery disease. 
The vessels most affected by PAD are large arteries, the aorta and arteries of the lower 
extremities. More than 90% of the atherosclerotic disease results in arterial problems 
in the lower extremities [70]. Also in these vessels atherosclerosis plays an important 
role in the hardening and narrowing of the arteries. The epidemiology, prognosis, 
pathophysiology, treatment, and prevention of PAD in relation to the metabolic 
syndrome have been less studied than the association between the metabolic 
syndrome and CHD. Since CHD and PAD occur in different vascular beds they 
might be affected in a different way by the metabolic syndrome. In addition, the exact 
pathways how the metabolic syndrome leads to CVD are currently unknown.   
1.5. Study population & Outline of this thesis 
The association between the metabolic syndrome and CVD and possible mechanisms 
were described in the previous paragraphs. In this thesis, we focused on the specific 
processes (inflammation, endothelial dysfunction, insulin resistance, dyslipidaemia and 
the complement system) that may play a role in linking the metabolic syndrome to 
CVD, CHD and PAD.  
1.5.1. Study population 
All studies described in this thesis were performed in the baseline measurements of 
the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM).  
The CODAM study (started in 1999) consists of subjects with an increased risk of 
T2DM and CVD [71-73]. In short, participants of a large ongoing cohort of the 
National Institute for Public Health and the Environment who were Caucasian, older 
than 40 years of age and had one or more risk factors (Table 1.2) were invited to 
participate in a screening for the CODAM study. During the screening phase all 
participants (n=2715) underwent an oral glucose tolerance test (OGTT, with capillary 
glucose measurements at t=0 and t=120 minutes). According to the 1999 WHO 
criteria [74], 226 (8.3%) were newly diagnosed with T2DM, 385 (14.2%) had impaired 
glucose tolerance (IGT), 215 (7.9%) had impaired fasting glucose (IFG) and 1889 
(69.6%) had normal glucose tolerance (NGT). All those screened with T2DM, a part 
of those screened with IGT/IFG and a random selection with NGT, were invited to 
participate in CODAM. To increase the power of the participants with T2DM 49 
participants who were known to have T2DM of recent onset were also invited. 
Eventually a total of 574 subjects were included in the CODAM study. Based on a 
second OGTT (with venous glucose measurements at t=0, 30, 60 and 120 minutes), 
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301 had NGT, 127 had impaired glucose metabolism (IGM; IGT and IFG combined) 
and 146 had T2DM (of whom 80 were newly diagnosed by screening, 20 had T2DM 
of recent onset, i.e. diabetes more than 1 year but less than 4 years and 46 had T2DM 
for 4 years or longer.  
 
Table 1.2: Inclusion criteria CODAM study 
Inclusion criteria 
> 40 years and 
either BMI > 25 kg/m2  
or positive family history of T2DM  
or history of gestational diabetes  
or use of antihypertensive medication  
or non-fasting blood glucose >6 mmol/L  
or glucosuria  
or a combination of the above 
 
 
All participants visited the laboratory twice. During the first visit, the participants 
handed in questionnaires on lifestyle factors and health status. Body weight and blood 
pressure were measured, and the 2nd OGTT was done. Blood samples were taken to 
determine various blood parameters including blood lipids, insulin, markers of 
inflammation and endothelial dysfunction. During the OGTT several questionnaires 
were filled in (about smoking habits, physical activity, WHO Rose angina 
questionnaire, health related quality of live, depression, medication, and food 
frequency questionnaire). During the second visit, blood pressure was measured again, 
carotid artery wall ultrasound measurements were taken as a surrogate marker of 
atherosclerosis, and ankle arm index (AAIx) was measured as a marker of peripheral 
arterial disease. Next, body height, body composition (skin fold thickness) and body 
fat distribution (waist and hip circumference, saggital and transversal diameter) were 
measured and a 12-lead rest electrocardiogram (ECG) was recorded. 
In the course of this PhD project, a 7 years follow-up examination has been 
completed but during preparation of this thesis, the data for longitudinal 
investigations were not yet available.  
1.5.2. Outline 
The central aim of this thesis was to identify pathways that can (partly) explain the 
association between the metabolic syndrome and cardiovascular disease. The analyses 
were done in a population with an elevated risk of T2DM (the CODAM study).  
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We investigated how different aspects of the metabolic syndrome are related to CVD 
and CVD risk associates. In Chapter 2 & 3 we investigated the association between 
the metabolic syndrome and two different aspects of CVD, i.e. coronary artery disease 
and peripheral arterial disease. In Chapter 2 we determined whether plasma markers 
of low-grade inflammation could explain, at least partly, the association between the 
metabolic syndrome and CVD. This was expanded in Chapter 3 by also investigating 
if endothelial dysfunction could also explain part of the association and whether it was 
additional to low-grade inflammation. In Chapter 4 we investigated whether 
complement C3 was associated with CHD.  
In Chapter 5 we focussed on the association between the metabolic syndrome and 
structural and metabolic intermediates of CVD. We report on the association of the 
metabolic syndrome with alanine-amino transferase as a marker of NAFLD which, in 
turn, is a risk factor for CVD. We determined if the association was explained by 
possible links between the metabolic syndrome and CVD, i.e. insulin resistance, low-
grade inflammation, endothelial dysfunction and NEFAs. In Chapter 6 we report on 
potential mechanisms relating human plasma complement C3 to insulin resistance. 
Finally, Chapter 7 summarizes and discusses the main findings of the studies included 
in this thesis and their implications in public health. 
1.6. References 
1  Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. 
Nature 2001;414(6865):782-787. 
2  Ezzati M, Lopez AD, Rodgers A, et al. Comparative quantification of health risks: global and 
regional burden of disease attribution to selected major risk factors. Geneva; 2004. 
3  Casanueva FF, Moreno B, Rodriguez-Azeredo R, et al. Relationship of abdominal obesity with 
cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol (Oxf) 2009; 
4  Caterson ID, Hubbard V, Bray GA, et al. Prevention Conference VII: Obesity, a worldwide 
epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. 
Circulation 2004;110(18):e476-483. 
5  Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 
participants from 52 countries: a case-control study. Lancet 2005;366(9497):1640-1649. 
6  Joslin EP. The prevention of diabetes mellitus. JAMA 1921;76(2):79-84. 
7  Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome. Zentralbl Inn 
Med 1923;44(105-127. 
8  Vague J. La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité. Presse Med 
1947;55(30):339. 
9  Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 
1988;37(12):1595-1607. 
General introduction 
19 
10  Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a 
WHO consultation. Diabet Med 1998;15(7):539-553. 
11  Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 
2005;366(9491):1059-1062. 
12  Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. 
European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16(5):442-443. 
13  Executive Summary of The Third Report of The National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III). Jama 2001;285(19):2486-2497. 
14  Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic 
syndrome: an American Heart Association/National Heart, Lung, and Blood Institute 
Scientific Statement. Circulation 2005;112(17):2735-2752. 
15  Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim 
statement of the International Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and International Association for the 
Study of Obesity. Circulation 2009;120(16):1640-1645. 
16  Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease 
prevention in clinical practice: executive summary. Atherosclerosis 2007;194(1):1-45. 
17  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and 
Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998;6 Suppl 
2(51S-209S. 
18  Oka R, Kobayashi J, Yagi K, et al. Reassessment of the cutoff values of waist circumference 
and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. 
Diabetes Res Clin Pract 2008;79(3):474-481. 
19  New criteria for 'obesity disease' in Japan. Circ J 2002;66(11):987-992. 
20  Khan NA, McAlister FA, Rabkin SW, et al. The 2006 Canadian Hypertension Education 
Program recommendations for the management of hypertension: Part II - Therapy. Can J 
Cardiol 2006;22(7):583-593. 
21  Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in 
European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes 
Metab 2002;28(5):364-376. 
22  Ghosh A, Liu T, Khoury MJ, et al. Family history of diabetes and prevalence of the metabolic 
syndrome in U.S. adults without diabetes: 6-year results from the National Health and 
Nutrition Examination Survey (1999-2004). Public Health Genomics 13(6):353-359. 
23  Welin L, Adlerberth A, Caidahl K, et al. Prevalence of cardiovascular risk factors and the 
metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public 
Health 2008;8(403. 
Chapter 1 
20 
24  Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary 
events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93(2):136-141. 
25  Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from 
coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 
2004;110(10):1245-1250. 
26  Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive 
protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary 
Prevention Study. Circulation 2003;108(4):414-419. 
27  Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and 
cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 
2004;27(11):2689-2694. 
28  Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint 
statement from the American Diabetes Association and the European Association for the 
Study of Diabetes. Diabetes Care 2005;28(9):2289-2304. 
29  Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve 
identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes 
Care 2004;27(11):2676-2681. 
30  Arsenault BJ, Pibarot P, Despres JP. The quest for the optimal assessment of global 
cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime? 
Cardiology 2009;113(1):35-49. 
31  Lau DC. Metabolic syndrome: perception or reality? Curr Atheroscler Rep 2009;11(4):264-271. 
32  Gustafson B, Gogg S, Hedjazifar S, et al. Inflammation and impaired adipogenesis in 
hypertrophic obesity in man. Am J Physiol Endocrinol Metab 2009; 
33  Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis 
factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95(5):2409-2415. 
34  Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human 
adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin 
Invest 1995;95(5):2111-2119. 
35  Gustafson B, Hammarstedt A, Andersson CX, et al. Inflamed adipose tissue: a culprit 
underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 
2007;27(11):2276-2283. 
36  Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 
2006;116(7):1793-1801. 
37  Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 
2005;115(5):1111-1119. 
38  Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin 
resistance. Nature 2002;420(6913):333-336. 
39  Werner ED, Lee J, Hansen L, et al. Insulin resistance due to phosphorylation of insulin 
receptor substrate-1 at serine 302. J Biol Chem 2004;279(34):35298-35305. 
General introduction 
21 
40  Jansson PA, Pellme F, Hammarstedt A, et al. A novel cellular marker of insulin resistance and 
early atherosclerosis in humans is related to impaired fat cell differentiation and low 
adiponectin. Faseb J 2003;17(11):1434-1440. 
41  Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic 
activation of IKK-beta and NF-kappaB. Nat Med 2005;11(2):183-190. 
42  Wajchenberg BL, Nery M, Cunha MR, et al. Adipose tissue at the crossroads in the 
development of the metabolic syndrome, inflammation and atherosclerosis. Arq Bras 
Endocrinol Metabol 2009;53(2):145-150. 
43  Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and 
imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol 
Metab 2009;94(9):3171-3182. 
44  Walport MJ. Complement. First of two parts. N Engl J Med 2001;344(14):1058-1066. 
45  Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344(15):1140-1144. 
46  Gabrielsson BG, Johansson JM, Lonn M, et al. High expression of complement components in 
omental adipose tissue in obese men. Obes Res 2003;11(6):699-708. 
47  Hoie EB, McGuire TR, Leuschen PM, et al. Pentoxifylline inhibits tumor necrosis factor-alpha 
induced synthesis of complement component C3 in human endothelial cells. Biol Pharm Bull 
2004;27(10):1670-1673. 
48  Muscari A, Antonelli S, Bianchi G, et al. Serum C3 is a stronger inflammatory marker of insulin 
resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: 
comparison study in an elderly population. Diabetes Care 2007;30(9):2362-2368. 
49  Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the 
fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 
2000;23(6):779-785. 
50  Engstrom G, Hedblad B, Janzon L, et al. Complement C3 and C4 in plasma and incidence of 
myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev 
Rehabil 2007;14(3):392-397. 
51  Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of 
myocardial infarction. Am J Med 1995;98(4):357-364. 
52  Mamane Y, Chung Chan C, Lavallee G, et al. The C3a anaphylatoxin receptor is a key mediator 
of insulin resistance and functions by modulating adipose tissue macrophage infiltration and 
activation. Diabetes 2009;58(9):2006-2017. 
53  Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is 
associated with activation of protein kinase C theta and alterations in the insulin signaling 
cascade. Diabetes 1999;48(6):1270-1274. 
54  Kim JK, Gimeno RE, Higashimori T, et al. Inactivation of fatty acid transport protein 1 
prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 2004;113(5):756-763. 
55  Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and 
secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 
2005;115(5):1343-1351. 
Chapter 1 
22 
56  Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. 
Hepatology 2007;46(4):1081-1090. 
57  Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 
1997;8(3):146-153. 
58  Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am 
J Cardiol 1998;81(4A):18B-25B. 
59  Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a 
systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113-1132. 
60  Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 
5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb 
Vasc Biol 1999;19(12):3071-3078. 
61  Langenberg C, Bergstrom J, Scheidt-Nave C, et al. Cardiovascular death and the metabolic 
syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 
2006;29(6):1363-1369. 
62  Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart 
disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191(2):391-396. 
63  Szeplaki G, Prohaszka Z, Duba J, et al. Association of high serum concentration of the third 
component of complement (C3) with pre-existing severe coronary artery disease and new 
vascular events in women. Atherosclerosis 2004;177(2):383-389. 
64  Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247(3):349-358. 
65  Eck SL, Perkins ND, Carr DP, et al. Inhibition of phorbol ester-induced cellular adhesion by 
competitive binding of NF-kappa B in vivo. Mol Cell Biol 1993;13(10):6530-6536. 
66  Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. N Engl J Med 
2000;342(12):836-843. 
67  Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison 
of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol 
screening as predictors of peripheral arterial disease. Jama 2001;285(19):2481-2485. 
68  van der Meer IM, Iglesias del Sol A, Hak AE, et al. Risk factors for progression of 
atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke 
2003;34(10):2374-2379. 
69  Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. 
Cardiovasc Diabetol 2002;1(1). 
70  Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002;106(6):V295-301. 
71  Corpeleijn E, van der Kallen CJ, Kruijshoop M, et al. Direct association of a promoter 
polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and 
insulin resistance. Diabet Med 2006;23(8):907-911. 
72  Kruijshoop M, Feskens EJ, Blaak EE, et al. Validation of capillary glucose measurements to 
detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 
2004;341(1-2):33-40. 
General introduction 
23 
73  van Greevenbroek MM, Vermeulen VM, Feskens EJ, et al. Genetic variation in thioredoxin 
interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in 
diabetes mellitus. Diabet Med 2007;24(5):498-504. 
74  WHO. Definition, diagnosis and classification of diabetes mellitus. Report of a WHO 
Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: 
WHO/NCD/NCS/992 1999. 

 Chapter 2  
Low-grade inflammation can partly explain the 
association between the metabolic syndrome 
and either coronary artery disease or severity of 
peripheral arterial disease: The CODAM study 
 
 
 
 
 
 
 
 
 
 
Marjon Jacobs, Marleen M van Greevenbroek, Carla J van der Kallen, Isabel Ferreira,  
Ellen E Blaak, Edith J Feskens, Eugene H Jansen, Casper G Schalkwijk, Coen D Stehouwer 
Eur J Clin Invest 2009;39(6):437-444 
Chapter 2 
26 
Abstract 
Background: Low-grade inflammation has been hypothesized to underlie the coronary artery 
disease (CAD) risk associated with the metabolic syndrome, but the evidence is not conclusive. 
For peripheral arterial disease (PAD; as measured by the ankle-arm index), this association has 
not been studied before. The aim was to study whether the association between the metabolic 
syndrome and CAD or the severity of PAD can be explained by low-grade inflammation. 
Methods: The CODAM (Cohort study Diabetes and Atherosclerosis Maastricht) population 
includes 574 subjects, with an increased risk of type 2 diabetes, of whom 560 were included in 
the analyses (343 males; age: 59.5 ± 7.0 years). The inflammation markers that were measured 
were C-reactive protein, interleukin 6, soluble vascular cell adhesion molecule-1, soluble 
intercellular adhesion molecule-1 and serum amyloid A. All analyses were adjusted for age, sex 
and smoking. Results: Logistic regression showed that the metabolic syndrome was 
significantly associated with CAD (odds ratio [OR]=1.86, 95% CI: 1.21; 2.84, p=0.004). 
Further adjustment for inflammatory status, as captured in a combination of the inflammation 
markers (using an averaged Z-score), resulted in significant associations of both the metabolic 
syndrome and inflammatory status with CAD (ORmetabolic syndrome (95% CI) = 1.58 (1.01; 2.46), 
p=0.044; ORinflammation (95% CI) = 1.59 (1.14; 2.21), p=0.007). Linear regression analysis 
showed similar results for the ankle-arm index. Conclusions: The association between the 
metabolic syndrome on the one hand and prevalence of CAD or the severity of PAD on the 
other can be partly but not completely, 26% and 29% respectively, explained by low-grade 
inflammation. 
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2.1. Introduction 
The metabolic syndrome affects at least one quarter of the population in developed 
countries and is associated with an increased risk of developing type 2 diabetes and 
cardiovascular disease [1-3]. The main components of the metabolic syndrome are 
abdominal obesity, hypertension, dyslipidemia and a disturbed glucose metabolism [4]. 
The underlying pathogenesis of the relation between the metabolic syndrome and 
coronary artery disease is unknown but it has been hypothesized that low-grade 
inflammation might be involved [5-12]. The relation between the metabolic syndrome 
and peripheral arterial disease has not been extensively addressed [13-16], but it is 
reasonable to hypothesize that similar mechanisms may be operative. 
Low-grade inflammation in particular has been hypothesized to not underlie only the 
pathogenesis of the metabolic syndrome but also its association with cardiovascular 
diseases [5, 6, 8, 10-12]. One important determinant of low-grade inflammation in the 
metabolic syndrome might be central obesity, because visceral adipose tissue may 
produce inflammatory mediators, which in turn induce the production of acute phase 
reactants in hepatocytes and endothelial cells. Indeed, the metabolic syndrome has 
been associated with markers of inflammatory activity such as C-reactive protein 
(CRP) [9, 17-25], interleukin 6 (IL6) [26, 27], serum amyloid A (SAA) [28, 29] and 
soluble adhesion molecules [7, 23, 25, 30]. 
In view of these considerations, we tested the hypothesis that the association between 
the metabolic syndrome on the one hand and coronary artery disease (CAD) or 
severity of peripheral arterial disease (PAD, as measured by the ankle-arm index 
[AAIx]) on the other can be explained by an increased inflammatory activity. We 
investigated this, cross-sectionally, in the Cohort study on Diabetes and 
Atherosclerosis Maastricht (CODAM).  
2.2. Materials and methods 
2.2.1. Subjects 
The CODAM cohort [31] consists of 574 subjects who were invited from a large 
population based cohort on the basis of an elevated risk for type 2 diabetes (T2DM) 
[32]. Inclusion criteria for our cohort were Caucasian ethnicity and age older than 40 
years and one or more of the following: body mass index (BMI) above 25 kg/m2, a 
positive family history for T2DM, a history of gestational diabetes, the use of anti-
hypertensive medication, a postprandial glucose above 6.0 mmol/L and/or glucosuria. 
After a first oral glucose tolerance test [33], 301 subjects had normal glucose tolerance, 
127 had impaired glucose metabolism (IGM) and 146 had T2DM. IGM was defined 
as subjects who had either impaired glucose tolerance or impaired fasting glucose. 
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55% of the T2DM subjects were not aware of their diabetes status prior to the 
screening. The study was approved by the local Medical Ethical Committee of 
Maastricht University. All subjects gave written informed consent. 
For the analyses 560 subjects were included. Eight subjects were excluded because of 
missing data on inflammation, 1 had missing data on the AAIx and another 2 had 
missing data on smoking. Three subjects had an AAIx ≥ 1.5 and were excluded 
because of probable arterial rigidity. 
2.2.2. Measurements 
Waist circumference was measured at the level midway between the lateral lower rib 
margin and the spina iliaca anterior superior. Blood pressure was measured twice on 
each visit after 5 minutes of rest with an oscillometric precision blood pressure 
instrument (Maxi stable 3, Speidel & Keller, currently: Welch Allyn Inc, Skaneateles 
Falls, New York, USA) on the right arm in the supine position. Furthermore systolic 
blood pressures were measured with a standard Doppler device (Mini Dopplex D900, 
Huntleigh Diagnostics Ltd, currently: E-Medical, Harmelen, the Netherlands) in the 
brachial arteries and twice in both the tibialis posterior and dorsalis pedis arteries of 
the lower extremities. The ankle-arm index was calculated for each leg by dividing the 
highest ankle pressure by the highest brachial pressure. The lowest AAIx of either leg 
was used in the analyses.  
Lipid lowering medication was stopped 14 days before the first visit and all other 
medication was stopped the day before the visit. Blood samples were obtained by 
venipuncture to determine glucose, cholesterol, triglycerides and inflammation 
markers (CRP, IL6, SAA, soluble vascular cell adhesion molecule-1 (sVCAM-1), and 
soluble intercellular adhesion molecule-1 (sICAM-1)). Glucose was measured in NaF-
KO (sodium fluoride – potassium oxalate) plasma by the hexokinase method [31, 34]. 
High-density lipoprotein cholesterol (HDL-cholesterol) and triglycerides were 
measured in ethylenediaminetetraacetic acid (EDTA) plasma by enzymatic methods 
(Roche, Mannheim, Germany) by the Department of Clinical Chemistry of the 
University Hospital Vrije Universiteit Amsterdam (The Netherlands). CRP was 
measured in serum with a high-sensitivity kit (Latex, Roche Diagnostics Nederland 
BV, Almere, The Netherlands). IL6 and sVCAM-1 were both measured in EDTA 
plasma with a high-sensitivity human Quantikine Enzyme-Linked Immuno Sorbent 
Assay (ELISA) kit (R&D systems, Minneapolis, Minnesota, USA). sICAM-1 and SAA 
were measured in EDTA plasma by ELISA (Biosource, Invitrogen, Carlsbad, 
California, USA). All inflammation markers were measured at the Laboratory of 
Toxicology, Genetics and Pathology of the National Public Health Institute, Bilthoven 
(The Netherlands). 
The metabolic syndrome was defined according to the American Heart Association 
and the National Heart, Lung and Blood Institute [35]. 
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Coronary artery disease was defined as self-reported myocardial infarction, bypass 
surgery of the coronary arteries, balloon dilatation or stent placement (through 
questionnaires) and/or presence of signs of myocardial infarction (Minnesota codes 1-
1 or 1-2) or ischemia (Minnesota codes 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1) on a 12-
lead ECG. For the major part of the cases (>75% of the subjects with self-reported 
coronary heart disease), the self-reports could be confirmed using available hospital 
registries.  
In the CODAM study, only 28 out of 574 subjects had AAIx < 0.9 (the traditional 
criterion for the diagnosis of PAD) and thus we lacked power to address the question 
on PAD as a categorical variable. Therefore we used AAIx as continuous variable for 
the severity of PAD. This is reasonable since formation of atherosclerosis is a 
continuous process and every decrease of the AAIx below 1.5 is a reflection of 
atherosclerosis [36, 37]. 
2.2.3. Statistical analysis 
Variables having a skewed distribution were log-transformed prior to further analyses. 
Firstly, logistic and linear regression analyses were used to analyse the relation between 
the metabolic syndrome on the one hand and CAD or the AAIx, respectively, on the 
other (model 1, Table 4). All analyses were adjusted for age, sex and smoking (pack-
years). Next, the association between the metabolic syndrome and markers of 
inflammation was investigated. Finally, the extent to which the association between 
the metabolic syndrome and CAD or the AAIx could be explained by inflammation 
was determined (in which case the regression coefficient of the metabolic syndrome 
was expected to be attenuated). P-values smaller than 0.05 were considered significant. 
Because the inflammation markers were measured only once, the associations between 
each inflammation markers with the study outcomes will tend to be underestimated. 
Therefore, a more robust measure reflective of subjects’ levels of low-grade 
inflammation was calculated on the basis of the values of the several markers of 
inflammation investigated. Specifically, we first standardized each inflammation 
marker (i.e. CRP, IL6, sVCAM-1, sICAM-1 and SAA) to comparable units, by 
converting them into z-scores [i.e. (the subjects’ observed value – mean value in the 
cohort)/cohort standard deviation], and then averaged these z-scores into a total 
inflammation score [38]. 
All statistical analyses were performed using the SPSS package version 13.0 (SPSS, 
Chicago, IL, USA). 
2.3. Results 
Table 2.1 shows the basic characteristics of the subjects according to the absence and 
presence of the metabolic syndrome. In total 560 subjects were included (343 males; 
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age: 59.5 ± 7.0 years), of whom 54% had the metabolic syndrome. There were 
significantly more subjects with impaired glucose metabolism in the group subjects 
with the metabolic syndrome vs. without (27.9% vs. 15.3%, p <0.001) and also more 
diabetics (39.7% vs. 7.1%, p <0.001). Also the prevalence of CAD was significantly 
higher in the group of subjects with the metabolic syndrome (28.9% vs. 16.9%, 
p=0.001) and they had a lower AAIx (1.07 vs. 1.11, p=0.001). 
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Table 2.1: Characteristics of the CODAM cohort according to the absence or presence of the metabolic 
syndrome (MetS) 
 without MetS 
(n = 255) 
with MetS 
(n = 305) 
p-value 
Male / Female 149/106 194/111 0.211 
Age (years) 58.8 ± 7.4 60.2 ± 6.6 0.026 
Smoking (pack-years)* 9.5 (0.0 – 26.4) 16.0 (0.0 – 34.0) 0.088 
Waist (cm) 92.1 ± 11.0 104.6 ± 10.6 <0.001 
HDL cholesterol (mmol/L) 1.39 ± 0.34 1.02 ± 0.25 <0.001 
Triglycerides (mmol/L)* 1.0 (0.8 – 1.4) 1.8 (1.4 – 2.2) <0.001 
Systolic blood pressure (mmHg) 134 ± 19 145 ± 17 <0.001 
Diastolic blood pressure (mmHg) 79 ± 9 84 ± 9 <0.001 
Fasting plasma glucose (mmol/L) 5.4 ± 0.77 6.6 ± 1.71 <0.001 
Use of antihypertensive medication (%) 23.9 47.5 <0.001 
Use of lipid-lowering medication (%) 11.8 24.3 <0.001 
Impaired glucose metabolism (%) 15.3 27.9 <0.001 
Type 2 Diabetes (%) 7.1 39.7 <0.001 
Coronary Artery Disease (%) 16.9 28.9 0.001 
Ankle-arm index 1.11 ± 0.11 1.07 ± 0.13 0.001 
C-reactive protein (μg/mL)* 2.0 (1.1 – 3.5) 3.1 (1.8 – 5.4) <0.001 
Interleukin 6 (pg/mL)* 1.2 (0.79 – 1.8) 1.6 (1.1 – 2.4) <0.001 
Soluble vascular cell adhesion molecule 1 (ng/mL)* 441 (376 – 512) 483 (396 – 576) <0.001 
Soluble intercellular adhesion molecule 1 (ng/mL)* 311 (272 – 364) 354 (306 – 419) <0.001 
Serum amyloid A (μg/mL)* 6.0 (3.7 – 13.5) 7.9 (4.6 – 14.5) 0.013 
 
Data presented as number, mean ± SD, median (interquartile range) or percentage;  
Probabilities for normal distributed continuous variables are from student t-tests and for categorical variables from 
Chi-square tests; 
*: data were log-transformed prior to analyses 
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The metabolic syndrome was a significant determinant of CAD (odds ratio (95% 
confidence interval) = 1.86 (1.21; 2.84); p = 0.004, after adjustment for age, sex and 
smoking) and also of the AAIx (linear regression coefficient β (95% confidence 
interval) = -0.035 (-0.055; -0.016); p <0.001, after adjustment for age, sex and 
smoking). 
We subsequently determined whether the metabolic syndrome was associated with the 
individual inflammation markers and with the inflammation score (Table 2.2). 
Analyses showed that the metabolic syndrome was associated with all five individual 
inflammation markers and also with the inflammation score. Furthermore we 
determined whether inflammation was associated with CAD or AAIx after adjustment 
for age, sex, smoking and the metabolic syndrome (Table 2.3). Analyses showed that 
IL6 and the inflammation score were associated with CAD whereas CRP, IL6 and the 
inflammation score were significantly, inversely associated with the AAIx. 
 
Table 2.2: Association between the metabolic syndrome and markers of inflammation 
Markers of inflammation  95%CI p-value 
CRP 0.506 0.344-0.668 <0.001 
IL6 0.379 0.216-0.542 <0.001 
sVCAM-1  0.238 0.084-0.391 0.002 
sICAM-1  0.549 0.388-0.710 <0.001 
SAA  0.202 0.040-0.364 0.014 
Total inflammation score 0.375 0.271-0.479 <0.001 
 
β: indicates differences in inflammatory markers (expressed in SD) between subjects with vs. without the metabolic 
syndrome; All analyses were adjusted for age, sex and smoking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Artery disease in the metabolic syndrome 
33 
Table 2.3: Association between inflammation and coronary artery disease (CAD) or ankle-arm index (AAIx) 
 Main outcomes 
 CAD AAIx 
Main determinant OR 95%CI p-value  95%CI p-value 
CRP 1.17 0.94-1.45 0.155 -0.017 -0.027; -0.007 0.001 
IL6 1.47 1.18-1.81 <0.001 -0.019 -0.029; -0.009 <0.001 
sVCAM-1 1.01 0.81-1.26 0.928 -0.002 -0.013; 0.008 0.666 
sICAM-1 1.22 0.99-1.50 0.065 -0.010 -0.020; 0.001 0.066 
SAA 1.23 0.995-1.52 0.056 -0.007 -0.017; 0.003 0.164 
ZInflammation  1.59 1.14-2.21 0.007 -0.027 -0.043; -0.011 0.001 
 
OR: indicates association of inflammatory markers or inflammation score per one SD change with CAD; β: indicates 
difference in AAIx per one SD change in inflammatory markers or inflammation score; All analyses were adjusted for 
age, sex, smoking and the metabolic syndrome 
 
Finally, we determined whether the association between the metabolic syndrome on 
the one hand and CAD or the AAIx on the other could be explained by inflammatory 
activity Table 2.4). When the overall score for the inflammatory status (Zinflammation) 
was included in the original logistic regression model (model 7, Table 2.4), the 
association of the metabolic syndrome with CAD remained significant (OR (95%CI) 
= 1.58 (1.01; 2.46), p=0.044). Note that the association of the metabolic syndrome 
with CAD decreased by about 26% (judged on the basis of changes in the magnitude 
of the regression coefficients) compared to model 1. Similarly, when the inflammation 
score was added to the linear regression model (model 7, Table 2.4), again the 
metabolic syndrome remained significantly associated with AAIx (βmetabolic syndrome 
(95%CI) = -0.025 (-0.046; -0.005), p=0.015), with a 29% reduction of the strength of 
the association between the metabolic syndrome and the severity of PAD. This 
implies that the association between the metabolic syndrome and CAD and the AAIx, 
respectively, can be partly but not completely explained by low-grade inflammation.  
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Table 2.4: Association between the metabolic syndrome and coronary artery disease (CAD) or ankle-arm 
index (AAIx) and the role of inflammation 
  Main outcomes 
  CAD AAIx 
Model Adjustments OR 95%CI p-value  95%CI p-value 
1 age, sex, smoking 1.86 1.21-2.84 0.004 -0.035 -0.055; -0.016 <0.001 
2 model 1 + CRP 1.73 1.12-2.67 0.014 -0.027 -0.047; -0.007 0.010 
3 model 1 + IL6 1.65 1.07-2.55 0.024 -0.028 -0.048; -0.008 0.005 
4 model 1 + sVCAM-1 1.85 1.21-2.84 0.005 -0.035 -0.055; -0.015 0.001 
5 model 1 + sICAM-1 1.67 1.07-2.59 0.023 -0.030 -0.051; -0.010 0.004 
6 model 1 + SAA 1.79 1.17-2.75 0.008 -0.034 -0.054; -0.014 0.001 
7 model 1 + inflammation score 1.58 1.01-2.46 0.044 -0.025 -0.046; -0.005 0.015 
 
OR: indicates association of the metabolic syndrome with CAD; β: indicates difference in ankle arm index (AAIx) 
between subjects with vs. without the metabolic syndrome 
2.3.1. Additional analyses 
The definition of the metabolic syndrome as used in the analyses already includes use 
of antihypertensive, lipid-lowering and blood glucose-lowering medication. Therefore 
they were not added as variables to the model. For the AAIx also an upper limit of 1.4 
or even 1.3 is used instead of 1.5. When 1.4 was used in our cohort, 559 subjects were 
included in the analyses instead of 550 subjects and 541 were included if a limit of 1.3 
was used. For both upper limits the results did not change (data not shown). 
2.4. Discussion 
The main finding of this study was that the association between the metabolic 
syndrome on the one hand and CAD or the severity of PAD (as measured by the 
AAIx) on the other can be partly, but not completely, explained by inflammatory 
activity. 
An important asset of our study was the use of a robust measure of low-grade 
inflammation by combining inflammation markers (CRP, IL6, sVCAM-1, sICAM-1 
and SAA) while most other studies reported on associations with single inflammation 
markers, primarily CRP [5, 6, 10, 12, 13, 39-41]. In general, our data are consistent 
with previous studies with respect to the association of both the metabolic syndrome 
[8, 11] and low-grade inflammation [5, 6, 8, 10-12, 30, 42-46] with CAD or the 
metabolic syndrome [13-16] and low-grade inflammation [13, 39-41, 47, 48] with 
PAD. CRP has generally been reported to remain associated with CAD even when the 
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metabolic syndrome was included in the analyses [5, 6, 10, 12], and a few studies have 
described similar results for IL6, sometimes in combination with CRP [8, 46] with 
similar results. An inflammation score has not been tested before. 
It is noteworthy that very few of these previous studies have actually addressed the 
hypothesis, and the extent to which, the association between the metabolic syndrome 
and CAD could be explained by low-grade inflammation, in which case the addition 
of inflammation markers to the model would result in an attenuation of the strength 
of the association between the metabolic syndrome and CAD. In our analyses, the 
general inflammation score was independently associated with both CAD and the 
metabolic syndrome and explained their relationship to some extent but not 
completely. In addition, no study has addressed an association of the metabolic 
syndrome and an inflammation score with PAD before. Most studies addressed either 
the association of the metabolic syndrome [13-16] with AAIx or the association of 
low-grade inflammation [13, 39-41, 47, 48] with AAIx. Because CAD and PAD can be 
viewed as different manifestations of a single pathophysiological entity, i.e. 
atherosclerotic disease, and indeed are closely related in middle-aged and elderly 
populations [49], it is reasonable to test the hypothesis that associations of PAD with 
the metabolic syndrome and inflammation may be similar to those with CAD. Indeed, 
our results support this hypothesis. Our findings thus show that the metabolic 
syndrome is a risk factor for both CAD and PAD, and that inflammation explains 
some of this risk, but other mechanisms linking the metabolic syndrome to CAD and 
PAD are likely to be at least as important as inflammatory activity. 
 Some limitations of our study are its cross-sectional design, which precludes 
conclusions on causality. Thus it cannot be excluded that part of the inflammatory 
response was caused by, rather than was a cause of, CAD or PAD. Prospective studies 
are needed to further evaluate this. Additionally, we studied middle-aged Caucasian 
individuals, and we therefore do not know whether our results can be extrapolated to 
other ethnicities or age groups. Furthermore, we studied five markers of inflammation 
but cannot exclude that additional inflammatory markers, which may reflect other 
components of the complex inflammatory response, might to some extent explain the 
association between the metabolic syndrome on the one hand and CAD or the 
severity of PAD on the other hand.  
In conclusion, both the metabolic syndrome and low-grade inflammation were 
associated with both CAD and the severity of PAD (as measured by the AAIx), 
respectively. The association between the metabolic syndrome and prevalence of 
CAD or the severity of PAD was explained partly but not completely by low-grade 
inflammation because a reduction in the regression coefficients for CAD and AAIx, 
respectively was found, while the metabolic syndrome did remain independently 
associated with the outcome.  
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Abstract 
Objective: The metabolic syndrome is associated with coronary artery disease (CAD) and with 
peripheral artery disease (PAD) but the underlying mechanisms explaining these associations 
have not yet been completely clarified. The aim was to investigate: 1) whether endothelial 
dysfunction can explain the association between the metabolic syndrome and CAD and/or the 
severity of PAD, as measured by the ankle-arm index (AAIx); and 2) whether any such 
mediation is independent of that from low-grade inflammation. Methods: We studied 539 
subjects (232 men) aged 59.4 ± 6.9 years, with an increased risk of type 2 diabetes and 
cardiovascular diseases. Endothelial dysfunction and inflammation scores were calculated from 
3 markers of endothelial dysfunction (soluble E-selectin, soluble vascular cell adhesion 
molecule-1 and von Willebrand factor) and 6 of inflammation (C-reactive protein, interleukin 
6, soluble intercellular adhesion molecule-1, serum amyloid A, ceruloplasmin, haptoglobin). 
The association between the metabolic syndrome and CAD and/or PAD, and the mediating 
role of endothelial dysfunction herein was examined with logistic and linear regression 
analyses, all adjusted for age, sex and smoking. Results: Subjects with the metabolic syndrome 
(n=289; 54%) had higher prevalence of CAD (OR (95%CI) = 1.75 (1.14; 2.69)) and lower 
AAIx (β (95% CI) = -0.036 (-0.056; -0.016)). Endothelial dysfunction explained 6% of the 
association between the metabolic syndrome and CAD, and 19% of the association with AAIx, 
whereas low-grade inflammation explained 26% and 28% of these associations, respectively. 
Together, the two scores explained 24% and 36% of the association between the metabolic 
syndrome and CAD and AAIx, respectively. Conclusion: Endothelial dysfunction explains part 
of association between the metabolic syndrome and the severity of PAD but is not involved in 
the association between the metabolic syndrome and CAD. This indicates that the 
pathophysiologies of coronary and peripheral artery disease are essentially distinct. 
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3.1. Introduction 
The metabolic syndrome affects at least one quarter of the population of developed 
countries and its prevalence is rapidly increasing. The metabolic syndrome is 
associated with an increased risk of type 2 diabetes mellitus (T2DM) as well as 
cardiovascular diseases (CVD) [1, 2], but the underlying mechanisms explaining these 
associations have not yet been completely clarified. 
The metabolic syndrome is associated with endothelial dysfunction and low-grade 
inflammation [3-5], which are key features in the pathophysiology of atherosclerosis 
and atherotrombosis [6-8]. Therefore, it is plausible to hypothesize that endothelial 
dysfunction and low-grade inflammation may explain, at least in part, the association 
between the metabolic syndrome and CVD. Indeed, several studies have supported 
the concept that low-grade inflammation mediates a part of the association between 
the metabolic syndrome and coronary artery disease (CAD) and peripheral arterial 
disease (PAD) [9-11]. Using an inflammation score that comprised 5 markers of 
inflammation, we recently showed that approximately 28% of the association between 
the metabolic syndrome and CAD or the severity of PAD was explained by low-grade 
inflammation [12]. However a great deal of these associations remained unexplained 
thus suggesting that other mechanisms must play a role as well. Endothelial 
dysfunction, which is associated with increased cardiovascular risk [13, 14] and is 
elevated in the metabolic syndrome [3, 5], is a good candidate in this respect. 
However, endothelial dysfunction and low-grade inflammation are closely related [15] 
and it is therefore not clear to what extent the two mechanisms represent distinct or 
overlapping pathways linking the metabolic syndrome to increased risk of CAD or 
PAD severity. 
In view of these considerations, we have therefore investigated first: the extent to 
which the association between the metabolic syndrome and CAD or the severity of 
PAD could be explained by endothelial dysfunction; and second: whether any such 
mediating role of endothelial dysfunction added to, or overlapped with, that already 
shown for low-grade inflammation. We addressed these questions, cross-sectionally, in 
the Cohort study on Diabetes and Atherosclerosis Maastricht (CODAM). 
3.2. Materials and methods 
3.2.1. Subjects and study design 
The CODAM study is an ongoing prospective cohort study in the Netherlands that 
was originally designed to study the effects of obesity, glucose tolerance, lipid 
metabolism, lifestyle and genetics on cardiovascular complications, and that has been 
described in detail elsewhere [16]. Briefly, between 1999 and 2001 subjects were 
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selected from a large population-based cohort on the basis of an elevated risk for type 
2 diabetes (T2DM) [17]. Inclusion criteria for our cohort were Caucasian ethnicity, age 
older than 40 years and one or more of the following: body mass index above 25 
kg/m2, a positive family history for T2DM, a history of gestational diabetes, use of 
anti-hypertensive medication, a postprandial glucose above 6.0 mmol/L and/or 
glucosuria. In total 574 subjects were included and were extensively characterized with 
regard to their metabolic, cardiovascular and lifestyle risk profiles during two visits to 
the University’s research unit [16]. The study was approved by the Medical Ethical 
Committee of the Maastricht University and all subjects gave written informed 
consent. 
The present study reports on cross-sectional analyses concerning 539 subjects (232 
men); those who had missing data on one or more of the markers of low-grade 
inflammation or endothelial dysfunction considered (n=30), in whom lifetime 
smoking exposure could not be ascertained (n=2), and who had an ankle-arm index 
(AAIx) ≥ 1.5, indicating probable arterial calcification (n=3) were excluded from the 
analyses. 
3.2.2. Metabolic syndrome 
The metabolic syndrome was defined according to the updated definition of the 
American Heart Association and the National Heart, Lung and Blood Institute 2005 
[18], as shown in Table 3.1. Waist circumference was measured at the level midway 
between the lateral lower rib margin and the spina iliaca anterior superior [19]. Blood 
pressure was measured twice on each visit after 5 minutes of rest with an oscillometric 
precision blood pressure instrument (Maxi stable 3, Speidel & Keller, currently: Welch 
Allyn Inc, Skaneateles Falls, New York, USA) on the right arm in the supine position. 
Smoking habits throughout life as well as the current use of medication was assessed 
by questionnaires. Subjects were asked to stop their lipid-lowering medication 14 days 
before the first visit and all other medication the day before the visit. Blood samples 
were obtained by venipuncture to determine glucose, cholesterol, and triglycerides as 
described in detail [12]. 
Endothelial dysfunction, artery disease and metabolic syndrome 
45 
Table 3.1: Cut-off values of the components of the metabolic syndrome [18] 
Component* Categorical cut off value 
Elevated waist circumference >102 cm in men 
> 88 cm in women 
Elevated triglycerides > 1.7 mmol/L, or on drug treatment for elevated triglycerides 
Reduced HDL-cholesterol < 1.03 mmol/L in men  
< 1.3 mmol/L in women, or on drug treatment for reduced HDL-cholesterol 
Elevated blood pressure > 130 mmHg systolic blood pressure 
> 85 mmHg diastolic blood pressure, or on drug treatment for elevated blood 
pressure 
Elevated fasting glucose > 100 mg/dL (5.6 mmol/L), or on drug treatment for elevated fasting blood 
glucose 
 
* any 3 out of 5 constitute diagnosis of the metabolic syndrome 
3.2.3. Coronary artery disease and peripheral arterial disease 
CAD was defined as self-reported myocardial infarction, bypass surgery of the 
coronary arteries, balloon dilatation or stent placement (through questionnaires) 
and/or the presence of signs of myocardial infarction (Minnesota codes 1-1 or 1-2) or 
ischemia (Minnesota codes 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1) on a 12-lead 
electrocardiogram [12]. 
PAD was defined as an AAIx < 0.9 or a non-traumatic amputation. Because only 28 
out of 539 subjects had PAD we lacked power to address the association between the 
metabolic syndrome and PAD as a dichotomous variable. Therefore we used AAIx as 
a continuous variable as a marker of the severity of PAD. This is reasonable since 
atherosclerosis is a continuous process and every decrease of the AAIx below 1.5 is a 
reflection of atherosclerosis [20, 21]. Systolic blood pressures were measured with a 
standard Doppler device (Mini Dopplex D900, Huntleigh Diagnostics Ltd, currently: 
E-Medical, Harmelen, the Netherlands) in the brachial arteries and twice in both the 
tibialis posterior and dorsalis pedis arteries of the lower extremities. The AAIx was 
calculated for each leg by dividing the highest ankle pressure by the highest brachial 
pressure [22]. The lowest AAIx of either leg was used in the analyses. 
3.2.4. Markers on low-grade inflammation and endothelial dysfunction 
We measured six markers of low-grade inflammation, i.e. C-reactive protein (CRP), 
interleukin 6 (IL6), serum amyloid A (SAA), soluble intercellular adhesion molecule-1 
(sICAM-1), ceruloplasmin and haptoglobin. These markers have been implicated in 
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various aspects of the general inflammatory response [23, 24]. In addition, we 
measured 3 markers of endothelial dysfunction, i.e. soluble E-selectin (sE-selectin), 
soluble vascular cell adhesion molecule-1 (sVCAM-1), and von Willebrand factor 
(vWF).  These circulating biomarkers have been associated with endothelial 
dysfunction in various studies [25-27]. Details describing the measurement of CRP, 
IL6, SAA, sICAM-1 and sVCAM-1 have been published before [12]. Haptoglobin and 
ceruloplasmin were measured in serum using Tina-quant haptoglobin and 
immunoturbidimetric assays, respectively (Roche Diagnostics Netherlands BV, 
Almere the Netherlands) on an automatic analyser. Soluble E-selectin was measured in 
EDTA plasma with an Elipair ELISA (Diaclone, Tepnel, Besancon Cedex, France). 
vWF was measured in citrate plasma as previously described [28].  
3.2.5. Statistical analysis 
Variables with a skewed distribution, i.e. triglycerides, CRP, IL6, sICAM-1, SAA, sE-
selectin, sVCAM-1 and vWF were log-transformed prior to further analyses. 
Comparisons of characteristics between subjects with vs. those without the metabolic 
syndrome were performed by means of Student’s t-tests for continuous variables and 
by Chi-square tests for categorical variables.  
We computed a general inflammation score by averaging the z-scores [i.e. (the 
subjects’ observed value – the mean value in the cohort) / standard deviation of the 
cohorts’ mean] of the six markers of low-grade inflammation considered (i.e. CRP, IL-
6, SAA, sICAM-1, ceruloplasmin and haptoglobin) [29]. Likewise, an endothelial 
dysfunction score was calculated by averaging the z-scores of sE-selectin, sVCAM-1 
and vWF.  These composite measures of inflammation and endothelial dysfunction 
were calculated to overcome the problems of multiple testing and misclassification, 
the later often leading to an underestimation of the strength of the associations that 
could occur when analysing each marker separately. Moreover, not one biomarker can 
be appointed that solely represents either endothelial dysfunction or a general 
inflammatory response. Our current approach aims to minimize that particular 
limitation of the use of biomarkers as surrogates of biological processes.  
Linear regression analyses were used to determine first, the association of the 
metabolic syndrome with CAD and AAIx and also the association of the metabolic 
syndrome with endothelial dysfunction and with low-grade inflammation. Next, we 
determined whether endothelial dysfunction and low-grade inflammation were 
associated with either CAD or AAIx, using logistic and linear regression analyses, 
respectively. Finally, we examined the extent to which the associations between the 
metabolic syndrome and CAD or the AAIx were explained by endothelial dysfunction 
(in which case the magnitude of the logistic or linear regression coefficient reflecting 
the association between the metabolic syndrome and study outcome was expected to 
be attenuated after adjustment for endothelial dysfunction), and the extent to which 
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any such mediation was additional to that from low-grade inflammation (by further 
adjusting the associations mentioned above for low-grade inflammation). All analyses 
were adjusted for age, sex and lifetime smoking (in pack-years). Since the definition of 
the metabolic syndrome already includes the use of anti-hypertensive, lipid-lowering 
and blood glucose-lowering medication, these were not added to the model as 
potential confounding variables. 
All statistical analyses were performed using the SPSS package version 15.0 (SPSS, 
Chicago, IL, USA) and statistically significance was set at p<0.05. 
3.3. Results 
Table 3.2 shows the general characteristics of the study population according to the 
presence (n=289, 54%) of the metabolic syndrome. As compared with individuals 
without, those with the metabolic syndrome more often had CAD (29.1% vs. 17.2%) 
and had significantly lower AAIx (1.08 ± 0.13 vs. 1.11 ± 0.11). Levels of all markers 
of low-grade inflammation and endothelial dysfunction were significantly higher in the 
subjects with the metabolic syndrome, except for ceruloplasmin. 
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Table 3.2: Characteristics of the CODAM study population according to the absence or presence of the 
metabolic syndrome (MetS) 
 without MetS 
(n = 250) 
with MetS 
(n = 289) 
p-value 
Men / Women (n) 146/104 186/103 0.156 
Age (years) 58.8 ± 7.3 60.2 ± 6.6 0.022 
Smoking status    
Never / ex- / current smokers (%) 35.2/46.4/18.4 23.5/55.0/21.4 0.012 
Lifetime smoking (pack-years)* 20.3 (10.0 –35.7) 25.0 (12.6 – 39.8) 0.052 
Waist (cm) 92.8 ± 9.9 104.7 ± 10.7 <0.001 
Body Mass Index 26.5 ± 3.4 30.2 ± 4.2 <0.001 
HDL cholesterol (mmol/L) 1.40 ± 0.34 1.02 ± 0.25 <0.001 
Triglycerides (mmol/L) 1.0 (0.8 – 1.4) 1.8 (1.4 – 2.2) <0.001 
Systolic blood pressure (mmHg) 134.3 ± 19.2 144.7 ± 16.8 <0.001 
Diastolic blood pressure (mmHg) 79.0 ± 8.6 84.0 ± 8.9 <0.001 
Fasting plasma glucose (mmol/L) 5.4 ± 0.8 6.6 ± 1.7 <0.001 
Use of antihypertensive medication (%) 23.6 48.4 <0.001 
Use of lipid-lowering medication (%) 12.0 25.3 <0.001 
Glucose metabolism status    
Normal / impaired / type 2 diabetes (%) 77.2/15.6/7.2 31.5/29.1/39.4 <0.001 
Coronary Artery Disease (%) 17.2 29.1 0.001 
Ankle-arm index 1.11 ± 0.11 1.08 ± 0.13 0.001 
C-reactive protein (μg/mL) 2.0 (1.1 – 3.5) 3.1 (1.8 – 5.4) <0.001 
Interleukin 6 (pg/mL) 1.14 (0.79 – 1.79) 1.66 (1.10 – 2.35) <0.001 
Soluble intercellular adhesion molecule-1 (ng/mL) 310 (272 – 363) 354 (306 – 413) <0.001 
Serum amyloid A (μg/mL) 6.1 (3.7 – 13.4) 7.8 (4.5 – 14.5) 0.018 
Ceruloplasmin (g/L) 0.27 ± 0.05 0.26 ± 0.06 0.303 
Haptoglobin (g/L) 1.17 ± 0.48 1.43 ± 0.51 <0.001 
Inflammation score -0.19 ± 0.63 0.16 ± 0.67 <0.001 
Soluble E-selectin (ng/mL) 66 (47 – 88) 94 (70 – 123) <0.001 
Soluble vascular cell adhesion molecule-1 (ng/mL) 441 (377 – 511) 479 (393 – 576) 0.001 
Von Willebrand factor (%) 110 (86 – 154) 124 (92 - 167) 0.038 
Endothelial dysfunction score -0.22 ± 0.56 0.19 ± 0.63 <0.001 
 
Data presented as number, mean ± SD, median (inter-quartile range) or percentage;  
* estimated among ever-smokers. 
Endothelial dysfunction, artery disease and metabolic syndrome 
49 
 
The metabolic syndrome was associated with CAD (odds ratio [OR] (95% CI) = 1.79 
(1.17; 2.76), p=0.008) and with AAIx (linear regression coefficient β (95% CI) =  
-0.036 (-0.056; -0.016), p=0.001) (Table 3.4, model 2). The metabolic syndrome was 
associated with endothelial dysfunction as well as with low-grade inflammation, after 
adjustment for age, sex and smoking (β (95% CI) = 0.365 (0.266; 0.464), and β (95% 
CI) = 0.352 (0.245; 0.459), respectively; both p<0.001). 
Inflammation but not endothelial dysfunction was significantly associated with CAD 
while both endothelial dysfunction and inflammation were significantly inversely 
associated with the AAIx. These associations were still significant after adjustments 
for other risk factors and the metabolic syndrome (Table 3.3).  
The magnitude of the associations between the metabolic syndrome and CAD and the 
AAIx were only slightly (6%) and modestly (19%) attenuated, respectively, when 
adjusted for endothelial dysfunction (Table 3.4, model 3 vs. model 2), but were 
attenuated by 24% and 28%, respectively, when adjusted for low-grade inflammation 
instead (Table 3.4, model 4 vs. model 2). Together, endothelial dysfunction and low-
grade inflammation explained 23% and 36% of the association between the metabolic 
syndrome and CAD and AAIx, respectively (Table 3.4, model 5 vs. model 2). After 
considering low-grade inflammation, endothelial dysfunction thus explained an 
additional 8% but none of the strength of the association between the metabolic 
syndrome and the AAIx and CAD, respectively. 
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3.3.1. Additional analyses 
Since the use of composite biomarkers is not a standard approach, we repeated our 
analyses using the individual markers of inflammation and endothelial dysfunction. 
The results of the combination of the separate markers was generally comparable to 
what was observed using the composite biomarkers; in addition to the 6 markers of 
inflammation, the 3 markers of endothelial dysfunction together mediated only a very 
limited part (i.e. 2.9%) of the association between the metabolic syndrome and CAD, 
while mediation of the association between the metabolic syndrome and PAD was 
more pronounced (11.1%). However, as mentioned before, this approach is less 
robust because of the problem of multiple testing (9 instead of 2 additional variables 
needed to be included in the analyses). 
Classification of biomarkers as markers of inflammation or endothelial dysfunction 
may to some extent appear somewhat arbitrary. With respect to the markers we used 
in our current study, there is not much discussion in the literature in the classification 
of E-selectin and vWF as markers of endothelial dysfunction rather than inflammation 
[26] or the classification of CRP, IL6, SAA, ceruloplasmin and haptoglobin as markers 
of general inflammation rather than endothelial dysfunction. The classification of the 
cellular adhesion molecules may be more unequivocal. In our cohort, sICAM-1 was 
more strongly correlated to the markers of low-grade inflammation while sVCAM-1 
was more strongly correlated with the markers of endothelial dysfunction (data not 
shown). Of note, when we repeated the analyses described herein, excluding sVCAM-
1 and sICAM-1 from the endothelial dysfunction and the low-grade inflammation 
scores, respectively, the results did not materially change: in addition to inflammation, 
endothelial dysfunction mediated only a very limited part (i.e. 1.5%) of the association 
between the metabolic syndrome and CAD, while the additional mediation by 
endothelial dysfunction of the association between the metabolic syndrome and PAD 
was more  pronounced (16.7%). 
As could be expected given the definition of the metabolic syndrome, the prevalence 
of T2DM differed between the subjects with and without the metabolic syndrome. 
However, when we repeated our final analyses with inclusion of T2DM as a covariate, 
mediation by endothelial dysfunction and low grade inflammation did not materially 
change from what was presented above (data not shown). 
3.4. Discussion 
We showed that endothelial dysfunction explained 19% (8% when additionally 
adjusted for low-grade inflammation) of the association between the metabolic 
syndrome and the severity of PAD, as measured by the AAIx. Part of this mediation 
was thus additional to low-grade inflammation. In contrast, endothelial dysfunction 
did not explain any part of the association between the metabolic syndrome and CAD. 
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To our knowledge, the mediating role of endothelial dysfunction in addition to that of 
low-grade inflammation in the association between the metabolic syndrome and CAD 
or severity of PAD has not previously been described. Several studies have assessed 
the association of low-grade inflammation and/or endothelial dysfunction with either 
the metabolic syndrome [3, 5, 9-11, 30, 31] or with CVD [10, 11, 13, 30, 32, 33], but 
these studies did not address their mediating role in the relation between the latter 
two. De Jager et al [32] did perform similar analyses as we present here, but their study 
investigated T2DM and did not focus on different aspects of macrovascular diseases. 
They showed that inflammation alone explained about 25% of the increase in 
cardiovascular mortalitiy risk conferred by T2DM while endothelial dysfunction and 
low-grade inflammation together explained about 43% [32]. Wild et al recently 
described a mediating role of inflammation and hemostatic factors on the association 
between the metabolic syndrome and PAD[34]; and although the association between 
the metabolic syndrome and PAD was not significant in their analyses, the hazard 
ratio was attenuated by almost 10% when both inflammatory markers and hemostatic 
factors were included in the model. 
In our current analyses, endothelial dysfunction was significantly associated with CAD 
in crude analyses, but the strength of this association was attenuated and statistical 
significance was lost after adjustment for age, sex and lifetime smoking. Previously 
published studies mostly used vWF as a marker of endothelial dysfunction. In line 
with our findings, several prospective studies reported significant associations between 
vWF and fatal and non-fatal coronary events [13, 35, 36] which were generally 
attenuated after adjustment for conventional risk factors. Only a limited number of 
mostly small studies investigated sE-selectin and/or sVCAM-1 as additional markers 
of endothelial dysfunction, but their associations with coronary events were less clear 
[37-39].  
In contrast to the association with CAD, the association we observed between 
endothelial dysfunction and the severity of PAD remained significant after adjustment 
for age, sex and lifetime smoking. In the literature, only limited data are available on 
the association between endothelial dysfunction and the severity of PAD, and again 
most studies used vWF as marker of endothelial dysfunction. Various studies 
described an association between vWF and PAD (mostly defined as AAIx <0.9) [14, 
33, 40], while the association of vWF with the AAIx, as a measure of the severity of 
PAD, is less consistent [41-43]. Of note, our current data also show that the 28 
subjects with PAD indeed had higher vWF levels than those without (data not 
shown).  
An important strength of our study was the use of 6 biomarkers of low-grade 
inflammation (CRP, IL6, sICAM-1, SAA, ceruloplasmin and haptoglobin) and 3 for 
endothelial dysfunction (sE-selectin, sVCAM-1 and vWF), combined into two robust 
measures. Our current analyses showed that plasma levels of the markers for 
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endothelial dysfunction were higher in subjects with CAD and with more severe PAD 
(crude associations, data not shown), similar to what we have shown before for 
markers of low-grade inflammation [12]. An important advantage of the use of z-
scores is that it is more robust than the separate markers and it limits the biological 
variation in the data. A potential disadvantage of the use of these biomarkers is that 
they provide an indirect measure of endothelial dysfunction in contrast to a functional 
test such as endothelium-dependent flow-mediated vasodilatation [44]. However, if 
biomarkers are a less powerful measure of endothelial dysfunction, the associations we 
found would underestimate the actual associations. So it might be that using a 
functional measure for endothelial dysfunction would result in stronger mediation by 
endothelial dysfunction. Additional limitations of our study include its cross-sectional 
design, which prohibits conclusions about causality. In other words, it cannot be 
excluded that part of the endothelial dysfunction was caused by, rather than was a 
cause of, PAD. Prospective studies are needed to further evaluate this. Since our study 
included a high-risk population, the extrapolation of our findings to other groups need 
to be made with caution. Lastly, we included only middle-aged Caucasian individuals, 
which prevents extrapolation of our results to populations in other age categories or 
with different ethnicities. 
In conclusion, we showed that endothelial dysfunction explained part of the 
association between the metabolic syndrome and the severity of PAD in addition to 
low-grade inflammation, while it did not explain any of the association between the 
metabolic syndrome and CAD. This implies that inflammation and endothelial 
dysfunction do, at least not entirely, represent the same pathway in the relation 
between the metabolic syndrome and PAD, and that the pathogenesis of coronary and 
peripheral artery disease differ in this respect. Since inflammation and endothelial 
dysfunction explain only part of the association between the metabolic syndrome and 
cardiovascular disease other possible mechanisms/pathways, such as effects of 
inflammatory adipokines, coagulation and fibrinolysis or other hemodynamic 
mechanisms need to be investigated. Whether improvement of endothelial 
dysfunction can prevent metabolic-syndrome-associated peripheral arterial disease 
needs further investigation. 
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Abstract 
Background: Complement C3 is an emerging risk factor for coronary heart disease (CHD) and 
is particularly increased in the metabolic syndrome. A direct effect of smoking on structure and 
function of complement C3 has been suggested. Hypothesis: Smoking behaviour may affect 
the cardiovascular risk that is associated with plasma complement C3. Methods: The 
association between plasma C3 and CHD was studied in the CODAM (Cohort on Diabetes 
and Atherosclerosis Maastricht) study population (n=562, 61% male) with examination of 
effect modification by smoking. Results: The overall prevalence of CHD was 23.3%. Higher 
plasma C3 levels were associated with a higher CHD prevalence, and there was a significant 
interaction with heavy smoking (p=0.01). In never & light smokers, the univariate OR for 
CHD per 1 s.d. (0.33 g/L) increase in C3 was 1.09 (95% confidence interval (CI) 0.85-1.41) 
(p=0.505) whereas in heavy smokers it was 2.05 (1.43-2.93) (p<0.001). The association in the 
group of heavy smokers remained significant (OR 2.38 (1.54-3.68), p<0.001) after adjustment 
for traditional risk factors for cardiovascular disease and also after further adjustment for other 
cardiometabolic risk factors, i.e. the metabolic syndrome, CRP and insulin resistance 
(HOMA2IR) (OR C3 between 2.16 and 2.29, all p≤0.001). In conclusion: Human plasma 
complement C3 is associated with prevalent CHD, but only in heavy smokers, and this 
association is independent of important metabolic cardiovascular risk factors. 
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4.1. Introduction  
Coronary heart disease (CHD) is increasingly perceived as a disease of the immune 
system because of the low-grade inflammation that is seen in individuals with 
established cardiovascular disease and in those at increased risk of CHD including 
individuals with the metabolic syndrome or type 2 diabetes (T2DM). The complement 
system is the major effector of the humeral arm of the immune system. Its third 
component (C3) plays a pivotal role in the complement cascade and is the most 
abundant complement protein in the circulation. Complement C3 is an emerging risk 
factor for CHD [1] and higher complement C3 levels predicted a higher risk of new 
CHD events in women who had received aorto-coronary bypass graft surgery [2]. 
Complement C3 is particularly increased in disorders that are characterized by insulin 
resistance such as T2DM and the metabolic syndrome [3-7]. The association between 
C3 and CHD has been reported to be independent of smoking, hypertension, 
cholesterol and diabetes [8-10], although recent data from a large prospective study 
suggested that it may not be independent of these CVD risk factors [11]. The exact 
nature of the relation between high plasma complement C3 levels and the prevalence 
of CHD remains to be clarified.  
We hypothesized that another strong risk factor for cardiovascular disease, i.e. 
smoking, may affect the cardiovascular risk associated with high complement C3 
levels. It has been shown that, at least in vitro, cigarette smoke can activate the 
alternative pathway of complement by modifying complement C3 [12-15]. In addition, 
tobacco glycoprotein can activate the classical complement pathway, possibly via 
direct interaction with complement component C1Q [16]. These effects of cigarette 
smoke could, theoretically, result in the generation of biologically active complement 
cleavage products and thus enhance the effect of complement on the risk of 
cardiovascular disease.    
In view of these considerations, we hypothesized that the expected association 
between complement C3 and CHD would not be the same in individuals with 
different smoking behaviour, i.e. that there would be effect modification of smoking 
and plasma complement C3 on the prevalence of CHD. We also evaluated whether 
this relation was confounded and/or mediated by known cardiometabolic risk factors 
such as the metabolic syndrome, inflammation and insulin resistance.   
4.2. Methods 
4.2.1. Study population 
The CODAM cohort (n=574) has been described in detail previously [17;18]. In 
short, participants were selected from a large population-based cohort [19]. Inclusion 
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criteria were Caucasian descent and age > 40 years and, in addition, at least one of the 
following criteria: body mass index (BMI) > 25 kg/m2; a positive family history of 
T2DM; a history of gestational diabetes and/or glucosuria; and use of anti-
hypertensive medication. Combinations of these separate inclusion criteria were also 
allowed.  Subjects were excluded if they had missing data on one or more of the 
biochemical and clinical markers that were used in the analyses. The present study 
population therefore consisted of 562 individuals. The study was approved by the 
local Medical Ethical Committee of the Maastricht University and the University 
Hospital. All individuals gave written informed consent.  
4.2.2. Individual characterization 
Individuals were asked to stop their lipid-lowering medication 14 days prior to blood 
withdrawal. According the results of a standard 75 g oral glucose tolerance test, 141 
subjects had T2DM [20]. Of these T2DM subjects, 54% were not aware of their 
diabetes status prior to the screening. BMI (kg/m2) was calculated from weight (kg) 
without shoes and wearing light indoor clothing and height (m). Waist was measured 
at the level midway between the lateral lower rib margin and the spina iliaca anterior 
superior. Blood pressure was measured twice on each visit after 5 minutes of rest with 
an oscillometric precision blood pressure instrument (Maxi stable 3, Speidel & Keller) 
on the right arm in the supine position. Presence of the metabolic syndrome was 
determined according to the National Cholesterol Education Program (NCEP) – 
(Adult Treatment Panel (ATP) III definition as modified by the American Heart 
Association (AHA) / National Heart, Lung and Blood Institute (NHLBI) [21].  
The main outcome of this study, coronary heart disease (CHD), was defined as the 
occurrence of previous myocardial infarction, bypass of the coronary arteries, 
percutaneous coronary intervention (ascertained by questionnaire) and/or the 
presence of signs of myocardial infarction (Minnesota codes 1-1 or 1-2) or ischemia 
(Minnesota codes 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1) on a 12-lead ECG. For the 
major part of the cases (>75% of individuals with CHD), the self-reports could be 
confirmed using available hospital registries. 
Smoking habits were determined with the help of an extensive questionnaire about 
current tobacco smoking, smoking in the past, and quitting attempts. Individuals were 
categorized into three groups: never, light and heavy smokers. Light smokers were 
defined as former or current smokers who smoked/smoke less than or equal to the 
median pack-years of cigars or cigarettes (one pack-year is 20 g of tobacco per day, 
smoked over a course of 1 year). Current or previous tobacco consumption by the 
former & current light smokers was 12.5 (7.0-17.8) (median (interquartile range)) 
pack-years. Heavy smokers are former & current smokers who smoked/smoke more 
than the median amount of pack-years (tobacco consumption by heavy smokers was 
39.0 (30.2-53.3) pack-years). It could not be assessed with certainty whether former 
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smokers have stopped smoking prior to or after their first event, since we did not 
obtain information on the year of the first cardiovascular event. In our current cross-
sectional analyses we assumed that a substantial part of the group of former smokers 
had stopped smoking after the cardiovascular event. For this reason, former and 
current smokers were collapsed into one group. We verified this assumption by 
calculating the cross-product of current smoking and plasma C3. 
4.2.3. Biochemical analyses 
After an overnight fast (12-14 hrs), venous blood was collected in pre-cooled EDTA 
vacutainer tubes. After centrifugation at 3600 g for 15 min at 4°C, plasma aliquots 
were stored at –80°C until use. All samples were thawed only once prior to plasma 
measurements. The main predictor in this study, complement C3 was measured in 
serum by autoanalyzer (Hitachi 912) using a Roche kit assays. The interassay variation 
of the C3 determination was 2.14% and the average C3 concentration of the reference 
serum was exactly as reported by the manufacturer (protein Precinorm; C3, 1.36 g/L).  
C-reactive protein (CRP) was also measured in serum using the CRP-Latex assay 
(Roche diagnostics). The following variables were determined in EDTA plasma; 
HDL-cholesterol using the HDL-C plus assay, cholesterol using the CHOD-PAP 
assay, triglycerides using the TG GPO-PAP assay. Plasma insulin concentrations were 
determined with a two-sided immunoradiometric test, using paired monoclonal 
antibodies (Medgenix Diagnostics). Glucose concentrations were measured in 
NaF/KOx plasma with the hexokinase glucose-6-phosphate dehydrogenase method 
(HK-G6PD method; ABX Diagnostics Glucose HK 125). Insulin sensitivity 
(homeostasis model assessment (HOMA)-insulin resistance (IR)) was estimated using 
the HOMA2 calculator (www.dtu.ox.ac.uk) based on the nonlinear computer model 
[22]. 
4.2.4. Statistical analyses 
Variables with a normal distribution are presented as mean ± standard deviation (SD). 
Variables with skewed distribution (i.e. insulin, HOMA2-IR, CRP and triglycerides) 
were log-transformed prior to further analyses. These variables are presented as 
median (interquartile range). Comparisons between different groups were assessed by 
Student’s t-test (continuous data) or χ2 tests (frequency data). A two-sided P-value 
<0.05 indicated statistical significance.  
In the logistic regression analyses, complement C3 was converted to a Z-score (unit is 
standard deviation, SD) which allowed us to present the main results of the logistic 
regression analyses as the change in OR for one SD increase in C3. First, logistic 
regression analyses were performed to analyse the association between C3 and CHD. 
Effect modification by smoking was investigated by adding interaction terms (the 
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cross-product of smoking and plasma C3) to the logistic regression model. When 
significant interaction (p<0.1) was present, we proceeded with stratified analyses with 
individuals divided into groups according to smoking behaviour. Analyses were 
performed with adjustments for age, sex, BMI, total cholesterol and T2DM (Y/N). 
Next, we investigated whether the observed associations were independent of 
cardiometabolic risk factors i.e. the metabolic syndrome, low-grade inflammation (as 
represented by CRP) and insulin resistance (HOMA2-IR). Use of antihypertensive and 
glucose-lowering medication were not included as covariates since these are included 
in the definition of the metabolic syndrome.   
All analyses were done using the Statistical Package for the Social Sciences (SPSS) 
version 15.0 for windows (SPSS Inc, Chicago IL, USA). 
4.3. Results 
In the whole population, plasma C3 concentration was significantly associated with a 
higher prevalence of CHD: the odds ratio (OR) for CHD per 1 SD (0.33 g/l) increase 
in C3 was 1.39 (95% CI: 1.14-1.68), p=0.001. This association remained significant 
(OR C3, 1.50 (1.18-1.90), p=0.001) after adjustment for relevant cardiovascular risk 
factors i.e. sex, age, BMI, cholesterol, T2DM and smoking behaviour (never, light or 
heavy smoker). 
Basic characteristics of the study population stratified by smoking behaviour are 
presented in Table 4.1. Addition of cross-products of smoking behaviour and plasma 
C3 to the logistic regression model revealed interaction between C3 and heavy 
smoking on the risk of prevalent CHD (p for interaction = 0.01), while there was no 
indication of interaction between C3 and light smoking (p for interaction = 0.51). 
Next, subjects were stratified into two groups; a group of heavy smokers and a group 
of light & never smokers. Addition of the cross-product of light smoking and plasma 
C3 to the logistic regression analyses of the light & never smokers again showed that 
there was no interaction between C3 and light smoking (p for interaction = 0.49). For 
this reason, further analyses were done in the “never” and “light” smokers combined 
into one group (n=366; 71 CHD cases) and in the group of heavy smokers (n=196; 60 
CHD cases). In never & light smokers, the univariate OR for CHD per 1 SD increase 
in C3 was 1.09 (0.85-1.41) (p=0.505) whereas in heavy smokers it was 2.05 (1.43-2.93) 
(p<0.001, Table 4.2, model 1), and remained significant (OR 2.38 (1.54-3.68), 
p<0.001, Table 4.2, model 2) after adjustment for traditional risk factors for 
cardiovascular disease (sex, age, total cholesterol, T2DM). For completion, separate 
analyses were done to confirm that the association between C3 and CHD in subjects 
who never smoked (n=165, 25 CHD cases, OR 1.28 (0.78; 2.09), p=0.33) and in the 
former & current light smokers (n=201, 46 CHD cases, OR 1.04 (0.67; 1.58), p=0.84) 
was indeed comparable (as already indicated by the non-significant cross-product of 
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light smoking and C3 as shown above). To substantiate our decision to combine the 
former & current smokers into one group, we also investigated the association in the 
former and current heavy smokers separately, and the adjusted OR’s for CHD per 1 
SD increase in C3 in these analyses were 2.34 (1.32-1.14) (35 CHD cases, p=0.004) 
and 2.53 (1.24-5.13) (25 CHD cases, p=0.010), respectively. The complete absence of 
interaction between current smoking and C3 on the prevalence of CHD (p for the 
cross-product = 0.75) indicated that these OR’s did not differ significantly. Taken 
together, a 1 SD increase in plasma C3 was associated with a 2 to 2.5-fold higher 
prevalence of CHD in heavy smokers, while in the never and light smokers a similar 
increase in C3 was essentially not associated with a higher prevalence of CHD.  
The heavy smokers, especially those with CHD, had besides higher C3 levels also 
more other cardiometabolic risk factors such as the metabolic syndrome, insulin 
resistance and low-grade inflammation (Table 4.1) and from various human studies, 
plasma C3 levels are known to be associated with these particular risk factors [3-7]. 
We therefore investigated whether the association between plasma complement C3 
and CHD in heavy smokers was independent of these cardiometabolic risk factors. 
When the metabolic syndrome was included in the model, the OR for C3 in the heavy 
smokers decreased only slightly, from 2.38 (1.54-3.68) to 2.19 (1.40-3.43) (Table 4.2, 
model 2 & 3). Likewise, after additional adjustments for inflammation and insulin 
resistance the OR’s were 2.29 (1.43-3.65) and 2.16 (1.37-3.40), respectively (Table 4.2, 
model 4 & 5). The association between C3 and CHD in heavy smoking also remained 
significant when all metabolic cardiovascular risk factors that were addressed were 
included simultaneously (Table 4.2, model 6). The association between C3 and CHD 
in the group of never & light smokers was and remained non-significant and very 
modest, if present at all (Table 4.2, models 1-6). There are indications in the literature 
that statin therapy might reduce plasma levels of complement C3 (23-25) and since a 
substantial number of subjects in our study received statin therapy (42% of the 
subjects with CHD, 11% of those without) this might to some extent have 
confounded our results. With additional adjustment of the full model in Table 4.2. 
(model 6) for statin therapy, the OR for C3 remained 1.73 (1.03; 2.92) (p=0.04).  
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4.4. Discussion  
The main conclusion of our current study is that human plasma complement C3 was 
indeed associated with prevalent CHD in our whole study population, but careful 
examination learned that this relation was only present in the group of heavy smokers. 
The association between C3 and prevalence of CHD was independent of 
cardiometabolic risk factors such as insulin resistance, systemic inflammation, and the 
metabolic syndrome.  
Complement C3 has been established as a cardiovascular risk associate in both cross-
sectional and in longitudinal studies. It is often regarded as a component of 
inflammatory activity and is also strongly associated with insulin resistance. Our 
findings of an overall association between C3 and CHD are in keeping with several 
studies that reported associations between C3 and prevalence or incidence of 
cardiovascular disease, independent of age, sex and a limited number of additional risk 
factors [1;2;8;26]. We have extended those currently available data by showing a strong 
effect-modification of smoking behaviour on the association between C3 and CHD. 
The association was, in fact, only present in the group of heavy smokers. This leads us 
to suggest that the previously-reported associations between C3 and CHD may, in 
fact, have also been restricted to individuals who were heavy smokers which raises the 
possibility that in these reports, the actual effect of C3 in specific risk groups may 
have been diluted. Moreover, part of the variation on the reported associations may be 
related to the relative number of smokers in the research populations.  
Our hypothesis that there may be effect-modification between smoking and C3 on 
prevalence of CHD was based on several papers that showed a direct effect of 
cigarette smoke, or constituents of cigarette smoke, on the structure and function of 
complement components, including C3 [12;13;16]. These effects of cigarette smoke 
could, theoretically, result in the generation of biologically active complement cleavage 
products and thus enhance the effect of complement on the risk of cardiovascular 
disease. Such an activation would not necessarily lead to a measurable consumption of 
C3 since the plasma concentration of C3 exceeds that of its activation products by 
>1000-fold [27;28]. In our view, activation of complement C3 (in subjects with high 
C3 levels) by (heavy) smoking may be one of the mechanisms by which smoking can 
enhance the inflammatory process in the atherosclerotic plaque and thereby affect 
plaque composition and vulnerability and increase the risk of CVD. An alternative 
explanation for our observations could be that smoking would not directly affect 
(activation of) the complement C3 protein itself, but rather that (heavy) smoking 
would induce oxidative stress and inflammatory processes in the plaque which might 
then affect the expression of complement regulators to an extent that it would no 
longer suffice to control complement activation, especially in those subjects with high 
complement C3 levels. Since we have used cross-sectional, observational data in our 
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current analyses, we can presently not differentiate between these alternative 
explanations and longitudinal and experimental data are needed for a final conclusion. 
It remains to be conclusively determined whether C3 is actually a causal player in the 
development of CHD, or rather an innocent bystander reflecting a yet unknown 
metabolic mechanism. Our current data suggest a causal relation in which structural 
changes in complement C3, induced by heavy smoking, may accelerate the 
atherosclerotic process, but only if plasma C3 concentrations are relatively high. Such 
an effect of cigarette smoke on complement C3 may take place at various distinct 
locations such as in the circulation, the lungs, or locally in the atherosclerotic plaque.  
A growing body of evidence suggests a role for C3 activation in plaque formation or 
progression, which implies that not C3 by itself, but rather its activation products C3a 
and C3b, which are generated upon cleavage of C3, may be involved in the 
atherothrombotic process. Association of complement factor C3b with lipid 
components in the vessel wall [29-31] may induce an atherosclerotic response and 
where no significant complement activation takes place in normal arteries, 
complement is extensively activated in atherosclerotic lesions and is especially strong 
in vulnerable and ruptured plaques [32-35]. Moreover, inhibition of C3 activation 
reduces vein graft atherosclerosis in apoE3-Leiden transgenic mice [36]. In addition, 
Kostner et al showed in a small group of patients that C3a may be higher in unstable 
than in stable angina pectoris [37].  
In this study we have identified a subgroup group of heavy smokers, i.e. those with 
high C3 levels, who have a particularly high risk of CHD. Note that we specifically 
addressed the question whether smoking would affect (i.e. strengthen) the association 
between high levels of C3 and CHD. We did not hypothesize or address the question 
whether (heavy) smoking would somehow lead to higher plasma C3 concentrations.  
Nevertheless, plasma levels of C3 in the former and current heavy smokers without 
CHD were similar to those in subjects who never smoked (Table 4.1). Indeed, linear 
regression analyses with adjustment for age, sex, T2DM, total cholesterol and BMI 
showed that in these subjects plasma C3 levels in former and current heavy smokers 
did not differ from those in subjects who never smoked (data not shown), which 
strongly suggests that the higher C3 levels in the heavy smokers with CHD are not 
caused by the smoking habit itself. Hence it is rather the combination of the presence 
of high C3 levels and the habit of heavy smoking that underlies an increased risk of 
CHD in those subjects. 
Potential limitations of our study lie in the fact that the CODAM population consisted 
of middle-aged Caucasian individuals with an increased T2DM and CHD risk profile 
and thus did not represent the general population. Also, given the cross-sectional 
design of our study, we cannot completely rule out the possibility that the association 
between C3 and CHD may in fact be caused by metabolic changes that can be 
induced in response to a myocardial infarction. However, we consider this highly 
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unlikely since in the group consisting of never & light smokers, plasma C3 
concentration did not differ between individuals with CHD and those without (Table 
4.1). Moreover, both prospective human data [2] as well as animal studies suggest a 
causal relation [36]. Smoking cessation is associated with a pronounced increase in 
body weight and since plasma C3 concentration is associated with obesity one could 
argue that our current findings may to some extent be related to changes in body 
weight due to smoking cessation after a cardiovascular event. However, plasma C3 
levels are consistently higher in the subjects with CHD, both in the former and in the 
current smokers, irrespective of the fact that the former smokers were indeed more 
obese, and in this group obesity did not differ between those with and without CHD 
(Table 4.1). This strongly suggests that the higher C3 levels in the heavy smokers with 
CHD are not due to increased body weight after smoking cessation. The plasma levels 
of complement C3 in the CODAM population are relatively high compared to some 
other studies [6;38]. This may be at least partly related to the fact that the CODAM 
subjects do not comprise a random sample of the general population, but are in fact 
selected for an increased risk of diabetes and cardiovascular disease. However, it is 
unlikely that these relatively high levels will have compromised our results since we 
obtained a low interassay coefficient of variation (2.14%), all samples were analyzed in 
a blinded fashion and all comparisons were made within the CODAM study 
population.  
In conclusion, we showed a cross-sectional association between human plasma 
complement C3 and prevalent CHD, but only in heavy smokers. This association was 
independent of systemic inflammation, insulin resistance and the metabolic syndrome. 
This independent association may be related to a direct effect of smoking on 
complement C3 or to other, yet to be identified mechanisms that may lead to 
complement activation in this particular group of subjects. To further pin-point 
whether this observed interaction between heavy smoking and complement C3 on 
CHD is indeed generalizable to other populations, it may be worthwhile to re-analyse 
the relation between C3 and CHD in previously-published cohorts with focus on 
interaction with smoking habits.  
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Abstract 
Objective: The metabolic syndrome is associated with non-alcoholic fatty liver disease 
(NAFLD) as well as with insulin resistance, inflammatory adipokines, endothelial dysfunction 
and higher plasma levels of non-esterified fatty acids (NEFA), all of which may also affect the 
development of NAFLD. Therefore we investigated to what extent the association between 
the metabolic syndrome and alanine aminotransferase (ALT, as a surrogate of NAFLD), can 
be explained by different metabolic intermediates of the metabolic syndrome. Materials and 
methods: Cross-sectional analyses in 434 subjects from the Cohort on Diabetes and 
Atherosclerosis Maastricht study (264 men, mean age 59.5±7.1 years). We used multiple linear 
regression analyses to investigate the association between the metabolic syndrome and ALT 
and the mediation role of potential mediators herein. The mediators considered were insulin 
resistance (HOMA2IR), an inflammatory adipokine score (based on interleukin 6, serum 
amyloid A, intercellular adhesion molecule, adiponectin and leptin), an endothelial dysfunction 
score (based on E-selectin, vascular cell adhesion molecule and von Willebrand factor) and 
plasma levels of NEFA. All analyses were adjusted for age, sex, smoking, alcohol consumption 
and use of medication. Results: Subjects with the metabolic syndrome (53.7%) had significantly 
higher levels of ALT (β=0.67 SD (95%CI: 0.49;0.85), p<0.001). Adjustment for insulin 
resistance attenuated this difference by 77.3% (to 0.15 SD (-0.04;0.35)). Attenuation by adipose 
tissue-associated inflammation, endothelial dysfunction and NEFA was more modest (20.7, 
13.1 and 9.5% respectively). Part of the attenuation by NEFA, but not of the other mediators, 
was additional to that of insulin resistance. Conclusions: Insulin resistance constitutes a key 
pathophysiological mechanism in the association between the metabolic syndrome and 
NAFLD (measured as ALT), which may operate through adipose tissue-associated 
inflammation and endothelial dysfunction and to a lesser extent through NEFA, which may 
have an independent role in the development of NAFLD in subjects with the metabolic 
syndrome. 
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5.1. Introduction 
The increasing prevalence of the metabolic syndrome draws a heavy burden on public 
health. Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder that 
affects up to 20-30% of the population in the developed world [1, 2] and is a very 
prevalent finding in subjects with the metabolic syndrome [3]. Given the frequency of 
NAFLD in obesity and type 2 diabetes (T2DM), the prevalence of NAFLD in the 
metabolic syndrome can be estimated to be at least 70-80% [4, 5]. 
NAFLD has a wide histological spectrum ranging from simple steatosis and non-
alcoholic steatohepatitis (NASH) to more progressive forms of the disease such as 
fibrosis and eventually cirrhosis. Patients with simple steatosis are, among others, 
characterized by the accumulation of triglycerides in hepatocytes, while in NASH the 
accumulation of fat is accompanied by hepatic inflammation [1]. The ‘gold standard’ 
to diagnose NAFLD is liver biopsy [1, 6]. However, this is an invasive procedure with 
risk of post-interventional bleeding and therefore not acceptable without clinical 
indication. Alternative methods to detect hepatic fat accumulation are used in 
epidemiological studies including imaging techniques and measurement of circulating 
markers such as alanine aminotransferase (ALT) [6-8].  
Several unfavourable metabolic syndrome-associated processes may affect the 
development of NAFLD. Insulin resistance is most likely involved in the initiation of 
hepatic steatosis, but NAFLD may in turn contribute to further progression of insulin 
resistance [9]. In adipose tissue, loss of insulin sensitivity can lead to increased release 
of non-esterified fatty acids (NEFA) in the circulation, which may be incorporated 
into hepatic triglycerides [10, 11]. In combination with insufficient elimination of 
triglycerides, probably caused by hepatic insulin resistance, this can contribute to the 
development of NAFLD. Inflammation of adipose tissue, as commonly seen in the 
metabolic syndrome [12], may also contribute to the development of NAFLD. This is 
firstly because adipose tissue-associated inflammation yields insulin resistant 
adipocytes by activating JNK and IKKβ pathways [13, 14], and secondly because 
inflammatory adipokines contribute to systemic low-grade inflammation that may 
trigger hepatic inflammation and hepatic insulin resistance and thereby predispose to 
NAFLD [15]. Another metabolic syndrome-associated process that may contribute to 
the development of NAFLD is (local) endothelial dysfunction. The liver is a highly-
perfused organ and disturbance of liver perfusion may disturb the delicate balance 
between the supply and removal of nutrients and metabolites [16]. Insulin resistance 
as well as the concomitant increase in NEFA may disturb microvascular function [17] 
and thereby possibly contribute to the development and/or progression of NAFLD 
[18]. The aforementioned pathways are not necessarily fully independent; they may 
also affect one another. 
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Taken together, the evidence so far suggests that insulin resistance, inflammatory 
adipokines, endothelial dysfunction, and NEFA may each explain, at least in part, the 
association between the metabolic syndrome and NAFLD. To gain more insight into 
these issues, we have determined the association between the metabolic syndrome and 
plasma ALT (as a systemic marker of NAFLD) and investigated the extent to which 
this association could be explained by insulin resistance, inflammatory adipokines, 
endothelial dysfunction, and/or NEFA.  
5.2. Materials and methods 
5.2.1. Subjects and study design 
Cross-sectional analyses were performed on data from the Cohort on Diabetes and 
Atherosclerosis Maastricht (CODAM) study, which includes 574 subjects with an 
elevated risk for T2DM and CVD as described in detail elsewhere [19]. In short, all 
subjects were Caucasian, older than 40 years and met at least one of the following 
criteria: body mass index above 25 kg/m2, a positive family history for T2DM, a 
history of gestational diabetes, use of anti-hypertensive medication, a postprandial 
glucose above 6.0 mmol/L and/or glycosuria. The study was approved by the Medical 
Ethical Committee of the Maastricht University and all subjects gave written informed 
consent. 
Subjects were excluded if they had missing data on one or more of the markers for 
insulin resistance, inflammatory adipokines, endothelial dysfunction and/or NEFA 
(n=44). Additionally subjects were excluded if they used insulin therapy (n=11) since 
in those subjects insulin resistance cannot be estimated by HOMA2IR. Next, those 
with self-reported liver disease (n=6), or alcohol consumption of more than 20 g/day 
(women) or 40 g/day (men) (n=79) were excluded, since this is the maximal amount 
of alcohol consumption that has been accepted in NAFLD [20]. The present study 
population therefore consisted of a total of 434 individuals. 
5.2.2. Laboratory measurements 
The metabolic syndrome was defined according to the updated definition of the 
American Heart Association and the National Heart, Lung and Blood Institute, 2005 
[21]. According to the results of a standard 75 g oral glucose tolerance test, 146 
subjects had T2DM [22]. Of these T2DM subjects, 55% were not aware of their 
diabetes status prior to the screening. Use of medication, smoking behaviour and 
alcohol consumption were assessed in extensive interview sessions and research-
assistant administered questionnaires. Waist circumference was measured at the level 
midway between the lateral lower rib margin and the spina iliaca anterior superior. 
Blood pressure was measured twice after 5 minutes of rest with an oscillometric 
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precision blood pressure instrument (Maxi stable 3, Speidel & Keller, currently: Welch 
Allyn Inc, Skaneateles Falls, New York, USA) on the right arm in the supine position.  
Subjects were asked to stop their lipid-lowering medication 14 days before the visit 
and all other medication was stopped the day before the visit (> 80% adherence). 
Blood samples were obtained by venipuncture to determine glucose, cholesterol, 
triglycerides, interleukin 6 (IL6), serum amyloid A (SAA), soluble intercellular 
adhesion molecule (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM-1) 
as described previously [23]. Adiponectin and leptin were measured by ELISA in 
EDTA plasma (BioVendor Laboratory Medicine, Brno, Czech Republic). sE-selectin 
was measured in EDTA plasma with a CD62-Elipair ELISA (Diaclone, Tepnel, 
Besancon Cedex, France). Von Willebrand factor (vWF) was measured in citrate 
plasma as described previously [24]. NEFA was measured in EDTA plasma using an 
enzymatic colorimetric method (NEFA-C, Wako Chemicals GmbH, Neuss, 
Germany) and ALT was measured in EDTA plasma as described before and used as a 
measure of hepatic fat accumulation [7]. Insulin was measured in EDTA plasma using 
a 2-sided radioimmunoassay (Medgenix Diagnostics, Brussels, Belgium). Insulin 
resistance was derived from the homeostasis model assessment (HOMA2IR) and was 
computed using software downloaded at http://www.dtu.ox.ac.uk.  
5.2.3. Statistical analysis 
Variables with a skewed distribution, i.e. triglycerides, ALT, HOMA2IR, IL6, SAA, 
sICAM-1, adiponectin, leptin, NEFA, sE-selectin, sVCAM-1 and vWF were log-
transformed prior to further analyses. Differences between the subjects with and 
without the metabolic syndrome were assessed by means of Student’s t tests for 
continuous variables and by Chi-square tests for categorical variables.  
Two composite measures (average z-scores) were calculated to reduce the problem of 
multiple testing. Firstly, an inflammatory adipokines score, which was the average of 
the z-scores of IL6, SAA, sICAM-1, leptin and the z-score of adiponectin multiplied 
by -1. These five markers have each been reported to be secreted by adipose tissue in 
relevant amounts and have inflammatory (IL6, SAA, sICAM-1, leptin) or anti-
inflammatory (adiponectin) properties [25-28]. We therefore considered these markers 
good representatives of adipose tissue-associated inflammation as often seen in the 
metabolic syndrome. And secondly, an endothelial dysfunction score as the average of 
the z-scores of sE-selectin, sVCAM-1 and vWF. In order to enable direct comparison 
of the strengths of all associations, z-scores were also calculated for HOMA2IR, 
NEFA and ALT.  
We used linear regression analyses to investigate the associations, first, between the 
metabolic syndrome (main independent variable) and ALT (main dependent variable); 
second, between the metabolic syndrome and the potential mediators, i.e. insulin 
resistance, inflammatory adipokines, endothelial dysfunction or NEFA; and third, 
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between the potential mediators and ALT. Finally we examined the extent to which 
the association between the metabolic syndrome and ALT was explained, i.e. 
potentially mediated, by the potential mediators considered. This was done by 
quantifying, in percentage, the attenuations in the magnitude of the linear regression 
coefficient reflecting the association between the metabolic syndrome and ALT after 
adjustment for those mediators. Since there was no interaction between sex and the 
metabolic syndrome in the association with ALT, analyses were conducted in the 
whole population. All analyses were adjusted for age, sex, smoking, alcohol 
consumption, and the use of lipid-lowering and antihypertensive medication. 
All statistical analyses were performed using the SPSS package version 15.0 (SPSS, 
Chicago, IL, USA) and statistical significance was set at p<0.05. 
5.3. Results 
The basic characteristics of the study population are shown in Table 5.1. The 
prevalence of the metabolic syndrome was 53.7%. Subjects with the metabolic 
syndrome had higher levels of plasma of ALT, NEFA and inflammatory adipokines, 
had worse endothelial function and were more insulin resistant compared with those 
without the metabolic syndrome.  
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Table 5.1: Characteristics of the CODAM cohort according to the absence or presence of the metabolic 
syndrome (MetS) 
 Without MetS 
(n=201) 
With MetS 
(n=233) 
p-value 
Men/Women (n) 119/82 145/88 0.519 
Age (years) 58.7 ± 7.5 60.2 ± 6.7 0.034 
Waist (cm) 93.0 ± 9.8 104.5 ± 10.8 <0.001 
HDL cholesterol (mmol/L) 1.36 ± 0.31 1.01 ± 0.25 <0.001 
Triglycerides (mmol/L) 1.1 (0.8 – 1.4) 1.8 (1.4 – 2.2) <0.001 
Systolic blood pressure (mmHg) 134 ± 19 145 ± 18 <0.001 
Diastolic blood pressure (mmHg) 79 ± 9 84 ± 9 <0.001 
Fasting plasma glucose (mmol/L) 5.4 ± 0.6 6.5 ± 1.6 <0.001 
Alanine aminotransferase (mmol/L) 18.5 (14.6 – 24.2) 23.8 (19.4 – 31.4) <0.001 
Use of anti-hypertensive medication (%) 23.9 50.2 <0.001 
Use of lipid-lowering medication (%) 12.9 23.2 0.006 
Type 2 diabetes (%) 6.0 36.5 <0.001 
HOMA2IR 0.89 (0.73 – 1.09) 1.5 (1.2 – 2.2) <0.001 
Soluble E-selectin (ng/mL) 68 (48 – 89) 91 (68 – 120) <0.001 
Soluble vascular cell adhesion molecule 1 (ng/mL) 447 (386 – 512) 474 (387 – 566) 0.021 
Von Willebrand factor (% of gold standard)  116 (92 – 159) 122 (93 – 163) 0.596 
Endothelial dysfunction score -0.17 ± 0.58 0.14 ± 0.62 <0.001 
Interleukin 6 (pg/mL) 1.1 (0.8 – 1.7) 1.6 (1.1 – 2.4) <0.001 
Serum amyloid A (μg/mL) 6.3 (4.0 – 15.0) 8.0 (4.6 – 14.6) 0.320 
Soluble intercellular adhesion molecule 1 (ng/mL) 315 (272 – 367) 356 (307 – 411) <0.001 
Adiponectin (μg/mL) 8.3 (6.4 – 11.5) 6.4 (4.3 – 8.2) <0.001 
Leptin (ng/mL) 7.2 (3.7 – 16.8) 13.0 (8.1 – 24.4) <0.001 
Inflammatory adipokine score -0.24 ± 0.52 0.21 ± 0.51 <0.001 
Non-esterified fatty acids (mmol/L) 0.47 (0.36 – 0.57) 0.52 (0.43 – 0.61) <0.001 
 
Data are expressed as n or frequency (%), mean ± standard deviation or median (inter-quartile range); 
HDL: high-density lipoprotein, HOMA2IR: homeostasis model assessment of insulin resistance 
 
After adjustment for age, sex, smoking, alcohol consumption, and use of lipid-
lowering and antihypertensive medication, subjects with the metabolic syndrome had 
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significantly higher levels of ALT than those without (linear regression coefficient β 
(95% CI)=0.67 SD (0.49; 0.85), p<0.001). The metabolic syndrome was also positively 
associated with insulin resistance, inflammatory adipokines, endothelial dysfunction, 
and NEFA (Table 5.2) and all these four potential mediators were also associated with 
ALT (Table 5.3, model 1), even after additional adjustment for the metabolic 
syndrome (Table 5.3, model 2).  
 
Table 5.2: Associations of the metabolic syndrome with insulin resistance, endothelial dysfunction, 
inflammatory adipokines and non-esterified fatty acids 
 Independent variable: metabolic syndrome 
Dependent variables β (95% CI) p-value 
HOMA2IR 1.094 (0.932; 1.255) <0.001 
Inflammatory adipokines 0.391 (0.291; 0.490) <0.001 
Endothelial dysfunction 0.212 (0.099; 0.324) <0.001 
Non-esterified fatty acids 0.363 (0.169; 0.558) <0.001 
 
All analyses were adjusted for age, sex, smoking, alcohol consumption, and use of lipid-lowering and antihypertensive 
medication; 
β indicates difference in dependent variable (expressed in SD) between subjects with vs. without the metabolic 
syndrome; HOMA2IR: homeostasis model assessment of insulin resistance 
 
Table 5.3: Associations of insulin resistance, endothelial dysfunction, inflammatory adipokines and non-
esterified fatty acids with ALT 
 Dependent variable: log-ALT 
 Model 1: adjusted for age, sex, 
smoking, alcohol consumption, 
medication 
Model 2: adjusted for age, sex, 
smoking, alcohol consumption, 
medication, metabolic syndrome 
Independent variables β (95% CI) p-value β (95% CI) p-value 
HOMA2IR 0.514 (0.432; 0.595) <0.001 0.472 (0.375; 0.569) <0.001 
Inflammatory adipokines 0.523 (0.358; 0.688) <0.001 0.355 (0.184; 0.525) <0.001 
Endothelial dysfunction 0.499 (0.347; 0.652) <0.001 0.413 (0.265; 0.561) <0.001 
Non-esterified fatty acids 0.229 (0.139; 0.319) <0.001 0.178 (0.092; 0.265) <0.001 
 
β indicates difference in log-ALT (expressed in SD (one SD equals 0.16 log(mmol/L))) per one SD increase in each 
independent variable; HOMA2IR: homeostasis model assessment of insulin resistance 
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The differences in ALT levels between subjects with and without the metabolic 
syndrome were attenuated by adjustment for insulin resistance (77.3%; Table 5.4, 
model 2), and to a lesser extent by adjustment for inflammatory adipokines (20.7%, 
model 3a), endothelial dysfunction (13.1%, model 4a), or NEFA (9.5%, model 5a). Of 
note, mediation by endothelial dysfunction (1.8%, model 3b) and inflammatory 
adipokines (-0.4%, model 4b) did not add to that by insulin resistance. This was 
different for NEFA, which by itself mediated 9.5% of the association and added 4.4% 
to the mediation of insulin resistance (model 5b).  
When the metabolic syndrome, insulin resistance, inflammatory adipokines, 
endothelial dysfunction, and NEFA were added in a full model including also age, sex, 
smoking, alcohol consumption, and use of lipid-lowering and antihypertensive 
medication, insulin resistance (0.41 (0.30; 0.51) p<0.001), endothelial dysfunction 
(0.21 (0.06; 0.036) p=0.005) and NEFA (0.13 (0.05; 0.21) p=0.002), but not the 
metabolic syndrome or inflammatory adipokines, were significantly associated with 
plasma ALT.  
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Table 5.4: Associations of the metabolic syndrome with alanine aminotransferase and the mediation by 
insulin resistance, endothelial dysfunction, inflammatory adipokines and non-esterified fatty acids 
 Independent variable: Metabolic syndrome 
Model Adjustments β (95% CI) p-value mediation* (%) additional 
mediation# (%) 
1 Age, sex, smoking, alcohol 
consumption, medication 
0.671 
(0.490; 0.851) 
<0.001   
2 Model 1 +  
HOMA2IR 
0.152 
(-0.043; 0.347) 
0.127 77.3  
3a Model 1 +  
inflammatory adipokines  
0.532 
(0.343; 0.721) 
<0.001 20.7  
3b Model 1 + HOMA2IR + 
inflammatory adipokines  
0.140 
(-0.056; 0.337) 
0.161 79.1 1.8 
4a Model 1 +  
endothelial dysfunction 
0.583 
(0.406; 0.760) 
<0.001 13.1  
4b Model 1 + HOMA2IR + 
endothelial dysfunction  
0.155 
(-0.038; 0.348) 
0.115 76.9 -0.4 
5a Model 1 +  
nonesterified fatty acids 
0.607 
(0.427; 0.786) 
<0.001 9.5  
5b Model 1 + HOMA2IR + 
nonesterified fatty acids  
0.123 
(-0.070; 0.317) 
0.211 81.7 4.4 
 
β indicates difference in alanine aminotransferase (expressed in SD) between subjects with vs. without the metabolic 
syndrome; HOMA2IR: Homeostasis model assessment of insulin resistance; 
*  indicates change in the magnitude of the regression coefficient (β) as compared to Model 1 (expressed in %); 
# indicates the difference in the % attenuation by: HOMA2IR and inflammatory adipokines (model 3b), by 
HOMA2IR and endothelial dysfunction (model 4b) or by HOMA2IR and nonesterified fatty acids (model 5b) in 
comparison to the % mediation by HOMA2IR only (model 2). 
5.3.1. Additional analyses 
In the above-described analyses we used an average z-score for inflammatory 
adipokines assuming that these markers represent adipose tissue-associated 
inflammation as often seen in the metabolic syndrome. To exclude that our current 
results merely represent general low-grade inflammation, the analyses were repeated 
with C-reactive protein (CRP) as potential mediator. CRP did not essentially mediate 
the association of the metabolic syndrome with ALT; mediation by CRP was 4.2%, as 
compared to the 20.7% that was observed for the inflammatory adipokine score.  
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It has been reported that plasma ALT levels may underestimate liver fat content in 
T2DM patients [29]. The analyses reported above were therefore repeated without 
subjects with T2DM and the results of these analyses did not materially differ from 
what was reported above. The analyses were also repeated with a more stringent cut-
off value for alcohol consumption i.e. by excluding all subjects who consume >20 g 
alcohol daily, since this is the proposed threshold to distinguish between non-
alcoholic and alcoholic FLD [20].  Again, the results of these analyses did not 
materially differ from what was reported above (data not shown).  
5.4. Discussion 
In this study we showed that among the several metabolic syndrome-associated 
processes that were investigated, insulin resistance was the strongest mediator of the 
association between the metabolic syndrome and ALT while inflammatory adipokines, 
endothelial dysfunction, and NEFA also explained a part of the association between 
the metabolic syndrome and ALT, but to a lesser extent. Inflammatory adipokines and 
endothelial dysfunction, however, did not add to the mediation by insulin resistance 
while approximately half of the mediation by NEFA was additional to that by insulin 
resistance.  
Because of well-known mutual relations between the metabolic syndrome, insulin 
resistance and steatosis [30], the strong mediation by insulin resistance was largely 
anticipated. A more interesting finding is that although inflammatory adipokines were 
by themselves moderate mediators of the association between the metabolic syndrome 
and ALT, this effect was abolished when insulin resistance was also included in the 
model. This suggests that these processes, at least partly, represent the same 
mechanism(s). The overlap between mediation by inflammatory adipokines and 
insulin resistance may be explained by the fact that compromised insulin signalling 
and/or hyperinsulinaemia coincide with an altered production of these adipokines. 
Data in the literature show that the production of leptin by human adipocytes is 
regulated by hyperinsulinaemia and/or insulin signalling [31] as is the production of 
adiponectin [32, 33] and IL6 [34, 35]. Insulin signalling affects ICAM expression in 
leucocytes [36] and high insulin concentrations increase the expression of ICAM on 
endothelial cells [37]. Some of these adipokines may subsequently or perhaps 
concomitantly worsen (adipose) insulin resistance via activation of inflammatory 
pathways [38]. Thus, our data suggest that inflammatory adipokines may be 
responsible for a part of the mediating effect of insulin resistance. Our finding that it 
is inflammation of adipose tissue rather than general inflammation accentuates the 
importance of adipose tissue dysfunction in the association of the metabolic syndrome 
with ALT, and supports the use of the inflammatory adipokine score.  
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The observed (modest) mediation by endothelial dysfunction in the association 
between the metabolic syndrome and ALT also disappeared after concomitant 
adjustments for insulin resistance. This may be explained by direct effects of 
hyperinsulinaemia and/or insulin signalling on endothelial dysfunction [39] and 
additionally by effects of inflammatory adipokines on endothelial dysfunction [40]. 
Since we have only systemic markers of endothelial dysfunction available and because 
of the cross-sectional design of our study, currently we can not distinguish between 
the possibility that local insulin resistance in the liver is causal in the generation of 
fatty liver and the alternative explanation that an overall status of endothelial 
dysfunction is merely a reflection of the insulin resistant state. Although this was not 
the primary aim of our analyses, we did observe that endothelial dysfunction was 
associated with ALT, independently of insulin resistance and the other potential 
mediators considered, suggesting that it can also be an operative pathophysiological 
mechanism linking risk factors other than the metabolic syndrome to ALT. Taken 
together, although these data must be interpreted with caution, our findings support 
the possibility that insulin resistance-associated adipose tissue inflammation and 
hepatic microvascular dysfunction might actually contribute to the development 
and/or progression of ALT/NAFLD in the metabolic syndrome.  
Increased plasma NEFA concentrations are a hallmark of the metabolic syndrome 
and it is generally accepted that plasma NEFA contribute to hepatic triglyceride 
accumulation and the development of NAFLD [10]. We had hypothesized that 
mediation of the association between the metabolic syndrome and ALT by NEFA 
would be similar to that by inflammatory adipokines because both adipose insulin 
resistance and adipose inflammation are known to induce fatty acid release from 
adipose tissue. However, NEFA mediated the association more modestly than 
inflammatory adipokines (9.5% vs. 20.7%), but despite this and in contrast to the 
latter, mediation by NEFA was not completely abolished in the presence of 
concomitant mediation by insulin resistance. Our data suggest that half of the 
mediation attributable to NEFA may occur via pathways included in the process of 
adipose tissue insulin resistance and inflammation, while the remaining half most likely 
occurs via an insulin resistance-independent mechanism. Data in the literature report 
that in upper-body obese women, upper-body subcutaneous, not visceral, fat was 
main source of plasma NEFA [41] and systemic NEFA have been reported to be a 
major source of the extrahepatic fatty acids that accumulate in NAFLD [10]. These 
NEFA may contribute to hepatic steatosis partly via increased insulin resistance and 
inflammation as described above and partly via direct uptake into hepatocytes. These 
latter associations of dietary fatty acids and direct uptake of subcutaneous adipose 
tissue-derived NEFA may also be reflected by the significant independent 
contribution of NEFA to plasma ALT levels in the full model (including all potential 
mediators).  
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In this study, we particularly focused on potential mediators that were not included in 
the metabolic syndrome since these may provide insight in the metabolic pathways 
that are intermediate between the metabolic syndrome and ALT levels. We did not 
investigate the extent to which each of the individual components of the metabolic 
syndrome contributed to the relation between the metabolic syndrome and ALT 
levels. Some prospective studies showed that plasma concentrations of ALT could 
predict the metabolic syndrome [42, 43]. The latter also showed that a substantial part 
of this association was explained by insulin resistance, which is in line with our current 
findings.   
A limitation of our study may be the use of ALT levels as a measure of hepatic fat 
accumulation. However, even though ALT levels are not the ideal measure of hepatic 
fat accumulation the associations of ALT with the metabolic syndrome and with 
insulin resistance, inflammation, NEFA and endothelial dysfunction, reported herein 
are in agreement with those reported by others when other measures for hepatic fat 
accumulation were used [9, 16, 44, 45]. Other limitations of our study include its 
cross-sectional design, which prohibits conclusions about causality, and the fact that 
we studied middle-aged Caucasians, which excludes extrapolation of our results to 
other age categories or other ethnicities.  
In conclusion, we showed that insulin resistance mediates up to 75-80% of the 
association of the metabolic syndrome with ALT. Our findings additionally suggest 
that insulin resistance, and its associated adipose tissue inflammation and endothelial 
dysfunction may contribute to the progression of fatty liver disease (measured as 
ALT), via a common pathophysiological mechanism while the effect of NEFA may be 
partly independent of insulin resistance. Treatment of insulin resistance, which may 
concomitantly ameliorate endothelial dysfunction and the amount of circulating 
inflammatory cytokines, thus remains a main target for interventions aiming at the 
prevention of NAFLD in these individuals. Circulating levels of NEFA may also 
constitute an additional treatment target. 
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Abstract 
Background: Complement C3, a central component of the innate immune system is increased 
in subjects with obesity and type 2 diabetes and is a novel risk factor for cardiovascular disease. 
We hypothesized that the strong association between insulin resistance and circulating 
amounts of C3 may be related to hepatic fat accumulation -independent of central obesity itself 
and of a general low-grade inflammatory response. Research question: To what extent is the 
association between insulin resistance and C3 explained by plasma levels of alanine 
aminotransferase (ALT) as a surrogate of hepatic fat accumulation. Methods: Cross-sectional 
analyses conducted in the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) 
study. Analyses were restricted to subjects with none-to-moderate alcohol consumption 
(n=453, 61.4% men). Multiple linear regression analyses were used to investigate the 
association between HOMA2IR (main determinant) and circulating complement C3 (main 
outcome), and the mediating role of ALT herein. All analyses were adjusted for age, sex, 
presence of T2DM or heart disease, use of medication, smoking, alcohol consumption, waist 
circumference and inflammation. Results: Insulin resistance (estimated as HOMA2IR) was 
strongly associated with circulating C3 (standardized regression coefficient β 0.40 (95% CI: 
0.30;0.49)) and also with ALT (β 0.44 (0.34;0.54)), both adjusted for the above-mentioned 
covariates. The association between HOMA2IR and C3 was attenuated after further 
adjustment for ALT (β decreased to 0.34 (0.24;0.44)). Concluding remarks: Plasma ALT can 
explain 14.2% of the strong association between insulin resistance and circulating 
concentrations of complement C3, independent of central obesity and general inflammation. 
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6.1. Introduction 
Complement C3 is an emerging risk factor for cardiometabolic diseases. Positive 
associations between circulating concentrations C3 and cardiovascular disease have 
been reported to be independent of traditional risk factors such as smoking, 
hypertension, cholesterol and diabetes [1-4], although data from a large prospective 
study suggested this association may actually not be independent of such factors [5]. 
Complement C3 is substantially increased in the circulation of subjects with the 
metabolic syndrome [6], is strongly associated with insulin resistance [7], and is a risk 
factor for development of hypertension and type 2 diabetes mellitus (T2DM) [8,9]. 
The role of complement C3 with respect to risk of disorders such as, the metabolic 
syndrome, T2DM and cardiovascular disease has been receiving considerable 
attention but the metabolic mechanisms that may underlie the increase in circulating 
concentrations of complement C3 in these related metabolic disorders are less well-
studied.  
Several common aspects of obesity-related metabolic disease may contribute to the 
increased amounts of circulating C3. Studies on the regulation of C3 production have 
largely focused on inflammatory and immune processes since complement C3 is an 
important component of the innate immune system and C3 production is indeed 
stimulated by cytokines [10-12]. The association between insulin resistance and C3 
may thus be explained as the result of a common antecessor since low-grade 
inflammation as seen in obesity-related metabolic disorders can induce both insulin 
resistance and C3 production. Alternatively, this association may, at least in part, be 
independent of low-grade inflammation since the association between insulin 
resistance and C3 was shown to be independent of C-reactive protein (CRP) [7]. In 
this line, some data, although limited, have suggested a direct effect of insulin on 
complement C3 production [13].   
The larger part of circulating C3 is most likely produced by the liver [14] and 
Sreekumar et al showed that C3 gene expression is increased in non-alcoholic 
steatohepatitis (NASH), which is included in the non-alcoholic fatty liver disease 
(NAFLD) spectrum [15]. Of note, obesity-related metabolic disorders have a very 
high prevalence of NAFLD, i.e. up to 80% [16,17] which underlines the potential 
regulatory role for hepatic fat in the increased levels of circulating C3 in these 
disorders. In addition, extra hepatic sources such as vascular endothelium [12,16] and 
adipose tissue [18,19] may also contribute to plasma C3. With respect to the latter, 
weight loss is associated with a reduction in circulating C3 concentration, independent 
of e.g. triglycerides and glucose [20] while C3 by itself may also comprise a risk factor 
for incurring weight gain [21].   
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Taken together, the evidence suggests that insulin resistance is a major determinant of 
circulating complement C3. However, the mechanisms through which insulin 
resistance may affect C3 levels have not been thoroughly studied. We have therefore 
investigated to what extent the association between insulin resistance and plasma 
complement C3 is explained by hepatic fat accumulation (as represented by plasma 
ALT levels), independent of central obesity and general low-grade inflammation that 
are generally present in insulin resistance.   
6.2. Methods 
6.2.1. Study population and design 
The CODAM (Cohort on Diabetes and Atherosclerosis Maastricht) study includes 
574 subjects with an elevated risk of T2DM and cardiovascular disease [22]. In short, 
participants were selected from a large population-based cohort [23]. Inclusion criteria 
were Caucasian descent and age > 40 years and, in addition, at least one of the 
following: body mass index (BMI) > 25 kg/m2; a positive family history of T2DM; a 
history of gestational diabetes and/or glucosuria; and use of anti-hypertensive 
medication. Combinations of these separate inclusion criteria were also allowed. Study 
participants were extensively characterized with regard to their metabolic, 
cardiovascular and lifestyle profiles during two visits to the University’s research unit. 
The present study reports on cross-sectional analyses concerning 453 individuals (278 
men). Subjects who had missing data on one or more of the markers used in the 
analyses (n=26), were on insulin therapy (n=13), had self-reported liver disease (n=7) 
or consumed more than 20 g/day (women) or 40 g/day (men) of alcohol i.e. the 
maximal amount of alcohol consumption that has been accepted in NAFLD [24] 
(n=75) were excluded from the analyses. The study was approved by the Medical 
Ethical Committee of the Maastricht University and all subjects gave written informed 
consent. Reporting of the study conforms to STROBE along with references to 
STROBE and the broader EQUATOR guidelines [25]. 
6.2.2. Laboratory measurements 
Subjects were asked to stop their lipid-lowering medication 14 days before the first 
visit and all other medication was stopped the day before the visit (> 80% adherence). 
Blood samples were obtained by venipuncture. Serum was allowed to clot at room 
temperature for 45 min, centrifuged at 3000 rpm for 15 min and serum aliquots were 
stored at –80°C until use. Complement C3 was measured in serum by auto analyzer 
(Hitachi 912) using a Roche kit assay. The interassay variation of the C3 determination 
was 2.14% and the average C3 concentration of the reference serum was exactly as 
reported by the manufacturer (protein Precinorm; C3, 1.36 g/L). Haptoglobin, 
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ceruloplasmin and high sensitive CRP were also determined in serum by auto analyzer 
(Hitachi 912), by using the Tina-Quant Ceruloplasmin assay and by using the CRP-
Latex assay, respectively (both Roche diagnostics). EDTA blood was collected in pre-
cooled tubes on ice, centrifuged at 3000 rpm for 15 min at 4°C and EDTA plasma 
aliquots were stored at –80°C until use. Plasma insulin concentrations were 
determined in EDTA plasma with a two-sided immunoradiometric test, using paired 
monoclonal antibodies (Medgenix Diagnostics). Glucose concentrations were 
measured in NaF/KOx plasma with the hexokinase glucose-6-phosphate 
dehydrogenase method (HK-G6PD method; ABX Diagnostics Glucose HK 125). 
Insulin resistance (IR) was estimated according to the homeostasis model assessment 
(HOMA) using the HOMA2 calculator (www.dtu.ox.ac.uk) [26]. The following 
variables were also determined in EDTA plasma; HDL-cholesterol (HDL-c) using the 
HDL-C plus assay, total cholesterol using the CHOD-PAP assay, and triglycerides 
(TG) using the TG GPO-PAP assay (all Roche diagnostics). High-sensitive interleukin 
6 (IL6, R&D) and serum amyloid A (SAA) and soluble intercellular adhesion molecule 
(sICAM) (Biosource) were measured using ELISA kits. Alanine aminotransferase 
(ALT) was measured in EDTA plasma as described before, and used as a measure of 
hepatic fat accumulation [27].  
Waist circumference was measured at the level midway between the lateral lower rib 
margin and the spina iliaca anterior superior. Height was measured with a stadiometer 
and weight with a scale with subjects in underwear. BMI was calculated as weight 
divided by height squared (kg/m2). Blood pressure was measured twice on each visit 
after 5 minutes of rest with an oscillometric precision blood pressure instrument 
(Maxi stable 3, Speidel & Keller) on the right arm with subjects in the supine position. 
Presence of the metabolic syndrome was determined according to the National 
Cholesterol Education Program (NCEP) – Adult Treatment Panel (ATP) III 
definition as modified by the American Heart Association (AHA) / National Heart, 
Lung and Blood Institute (NHLBI) [28]. Prior cardiovascular disease (CVD) was 
defined as self-reported myocardial infarction, bypass surgery of the coronary arteries, 
balloon dilatation, stent placement, stroke or transient ischemic attack (through 
questionnaires) and/or the presence of signs of myocardial infarction (Minnesota 
codes 1-1 or 1-2) or ischaemia (Minnesota codes 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1) 
on a 12-lead electrocardiogram and (from subjects disease history questionnaire) 
and/or amputation for non-traumatic reasons and/or ankle-arm-index (AAIx) < 0.9. 
For most of the cases (> 75% of the subjects with self-reported CVD), the self-
reports could be confirmed using available hospital registries. Smoking habits were 
determined with the help of an extensive questionnaire about current tobacco 
smoking, smoking in the past, and quitting attempts. Alcohol consumption was 
assessed by a validated food frequency questionnaire [29]. 
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6.2.3. Statistical analysis 
Variables with a skewed distribution (i.e. insulin, HOMA2IR, ALT, CRP, SAA, IL6 
and sICAM) were log-transformed prior to further analyses. Subject characteristics 
were compared across tertiles of C3 concentrations by means of ANOVA for 
continuous variables or by Chi2 tests for categorical variables. We computed a general 
inflammation score by averaging the z-scores (i.e. (the subject’s observed value – 
mean value in the cohort) ⁄ cohort SD) of the six markers of low-grade inflammation 
considered. This composite measure of inflammation was calculated to overcome the 
problems of multiple testing and misclassification that that could occur when 
analyzing each marker separately. To be able to directly compare the strengths of all 
associations, z-scores were also calculated for waist, HOMA2IR, C3 and ALT. 
Linear regression analyses were used to determine: firstly, the association between the 
main determinant, i.e. HOMA2IR, and the main study outcome, i.e. complement C3; 
secondly, the association between HOMA2IR and ALT; and thirdly, between the ALT 
and C3. Finally we examined the extent to which the association between HOMA2IR 
and C3 was explained, i.e. mediated, by ALT in which case magnitude of the linear 
regression coefficient reflecting the association between HOMA2IR and C3 would be 
attenuated after further adjustment for ALT. All analyses were adjusted for age, sex, 
presence of T2DM or prior CVD, use of lipid-lowering, glucose lowering and/or anti-
hypertensive medication, current smoking status (yes/no), alcohol consumption (in 
g/day), waist and general inflammation score. All statistical analyses were performed 
using the SPSS package version 15.0 (SPSS, Chicago, IL, USA) and statistical 
significance was set at p<0.05. 
6.3. Results 
General characteristics of the study population are shown in Table 6.1. Subjects with 
higher C3 concentrations were older, more insulin resistant, more obese, had higher 
circulating concentrations of inflammation-associated factors (i.e. inflammatory 
cytokines and acute phase response proteins) and more often had CVD, T2DM and 
the metabolic syndrome.  
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Table 6.1: General characteristics of the study population 
 Tertiles of C3 concentration 
 Lowest 
(n=149) 
Middle 
(n=155) 
Highest 
(n=149) 
P for 
trend 
Age (years) 58.7 ± 7.6 60.2 ± 6.9 59.8 ± 6.7 0.122 
Sex (% male) 65.8 61.3 57.0 0.302 
Current smoker 23.5 18.1 18.8 0.444 
BMI (kg/m2) 26.7 ± 3.4 28.5 ± 3.5 30.6 ± 4.9 <0.001 
Waist (cm) 93.7 ± 10.9 99.6 ± 9.3 104.3 ± 12.3 <0.001 
Insulin (pM) 46 (38; 57) 61 (48; 83) 85 (65; 120) <0.001 
HOMA2IR 0.88 (0.73; 1.08) 1.19 (0.94; 1.62) 1.69 (1.25; 2.32) <0.001 
C3 (g/L) 1.44 ± 0.13 1.78 ± 0.10 2.18 ± 0.21 <0.001 
Alanine aminotransferase (U/L) 18.8 (14.5; 25.0) 22.0 (18.0; 26.5) 24.6 (19.4; 32.4) <0.001 
C-reactive protein (μg/mL) 1.61 (0.96; 2.96) 2.76 (1.41; 4.69) 3.67 (2.20; 7.14) <0.001 
Interleukin 6 (pg/mL) 1.18 (0.81; 1.89) 1.41 (0.98; 2.11) 1.58 (1.03; 2.43) 0.002 
Soluble intercellular adhesion molecule 
(ng/mL) 
323 (277; 367) 318 (283; 376) 373 (309; 420) <0.001 
Serum amyloid A (µg/mL) 6.0 (3.6; 11.7) 6.5 (4.1; 13.8) 10.3 (5.5; 16.9) <0.001 
Ceruloplasmin (g/L) 0.25 ± 0.04 0.26 ± 0.04 0.29 ± 0.07 <0.001 
Haptoglobin (g/L) 1.09 ± 0.45 1.33 ± 0.46 1.55 ± 0.55 <0.001 
General inflammation score -0.32 ± 0.57 -0.03 ± 0.53 0.36 ± 0.72 <0.001 
Cardiovascular disease (%) 20.8 25.8 40.9 <0.001 
Metabolic syndrome (%) 26.8 57.4 81.2 <0.001 
Type 2 DM (%) 14.8 23.2 30.9 0.004 
Use of glucose-lowering medication (%) 8.1 12.9 15.4 0.140 
Use of lipid-lowering medication (%) 8.7 20.6 26.8 <0.001 
Use of anti-hypertensive medication (%) 25.5 49.3 51.0 <0.001 
 
Data are frequency (in %), mean ± SD or median [interquartile-range], as appropriate. Lowest C3 tertile ranged from 
1.01 through 1.63 g/L, middle tertile from 1.64 through 1.94 g/L and highest tertile from 1.95 through 3.35 g/L 
 
The standardized value (z-score) for logHOMA2IR was positively and strongly 
associated with standardized C3 (standardized regression coefficient β (95% 
confidence interval (CI)) for HOMA2IR was 0.55 (0.48; 0.63), p<0.001). This means 
that for every 1 SD increase in logHOMA2IR there was a 0.55 SD increase in 
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circulating C3. The positive association between HOMA2IR and C3 was somewhat 
more pronounced in women than in men (Figure 6.1). This association remained 
significant after adjustment for age, sex, T2DM, CVD, use of medication, smoking, 
alcohol consumption, waist, and general inflammation (β (95% CI) for HOMA2IR 
was 0.40 (0.30; 0.49), p<0.001, Table 6.2). After adjustment for all these variables, 
HOMA2IR was also associated with the potential mediator, ALT (β (95% CI) for 
HOMA2IR 0.44 (0.34; 0.54) p<0.001). ALT was also associated with C3, after 
adjustment for the covariates listed above (β (95% CI) for ALT 0.25 (0.17; 0.33) 
p<0.001) and remained so after additional adjustment for HOMA2IR (0.13 (0.05; 
0.22) p=0.002).  
 
Table 6.2: Independent association between HOMA2IR and complement C3 
  Complement C3 is outcome 
Model   ß HOMA (95% CI) p-value 
1 Crude 0.552 (0.475; 0.629) <0.001 
2 Model 1 + age, sex 0.564 (0.488; 0.640) <0.001 
3 Model 2 + T2DM, CAD, use of medication 0.544 (0.462; 0.627) <0.001 
4 Model 3 + smoking, alcohol consumption 0.534 (0.450; 0.618) <0.001 
5 Model 4 + waist 0.435 (0.337; 0.533) <0.001 
6 Model 5 + general inflammation 0.395 (0.302; 0.487) <0.001 
 
ß: standardized regression coefficient represents the increase in circulating C3 (in SD) per 1 SD increase in log; 
HOMA2IR: adjusted for the variables mentioned in the different models 
 
The associations between HOMA2IR and C3 reported above were attenuated by ALT 
regardless of additional adjustments for central obesity and/or inflammation (Table 
6.3). In the full model (Table 6.3, Model 3) mediation by ALT was 14.2%. Of note, in 
the final model (Table 6.3, Model 3 + ALT), besides HOMA2IR and ALT also 
general inflammation, waist, sex and use of glucose- and lipid lowering medication 
were significantly associated with C3 while age, T2DM, CVD, use of anti-hypertensive 
medication, smoking and alcohol consumption were not independently associated 
with C3. 
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Table 6.3: Association between HOMA2IR and C3 and the mediating role of ALT herein, independent of 
central obesity and inflammation 
 C3 is outcome 
 ß HOMA (95% CI) p-value Mediation† 
Model 1 0.534 (0.450; 0.618) <0.001 n.a. 
Model 1 + ALT 0.465 (0.371; 0.559) <0.001 12.9 % 
Model 2 0.435 (0.337; 0.533) <0.001 n.a. 
Model 2 + ALT 0.377 (0.272; 0.482) <0.001 13.3 % 
Model 3 0.395 (0.302; 0.487) <0.001 n.a. 
Model 3 + ALT 0.339 (0.241; 0.437) <0.001 14.2 % 
 
Model 1: analyses were adjusted for age, sex, T2DM, CVD, use of medication, smoking and alcohol consumption (= 
model 4 from Table 6.2); Model 2: analyses were adjusted for age, sex, T2DM, CVD, use of medication, smoking, 
alcohol consumption and waist (= model 5 from Table 6.2); Model 3: analyses were adjusted for age, sex, T2DM, 
CVD, use of medication, smoking, alcohol consumption, waist and general inflammation score (= model 6 from Table 
6.2);  
ß: standardized regression coefficient represents the increase in circulating C3 (in SD) per 1 SD increase in log 
HOMA2IR;  
† indicates change in the magnitude of the change in regression coefficient (β) after inclusion of ALT as compared to 
Models 1, 2, 3 without ALT, respectively (expressed in %). 
 
Since we observed that the association between HOMA2IR and C3 was more 
pronounced in women than in men (Figure 6.1), we also investigated whether the 
associations between HOMA2IR and C3, and the potential role of ALT herein, 
differed between men and women. Although the strength of the association between 
HOMA2IR and C3 was stronger in women (β (95% CI) for HOMA2IR was 0.53 
(0.35; 0.70), p<0.001, adjusting for all above-mentioned covariates except sex) than in 
men (β (95% CI) for HOMA2IR was 0.29 (0.18; 0.40), p<0.001), the attenuation of 
the strength of this association by ALT was similar between the sexes (women 13.9% 
and men 15.2%). 
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Figure 6.1: In the whole group, the linear regression coefficient β for the Z score of log HOMA2IR was 0.55 (95% CI 
0.48; 0.63) (p<0.001) n=453). The association between HOMA2IR and C3 was stronger in women (β was 0.78 (95% 
CI 0.64; 0.92) (p<0.001) n=175) than in men (β was 0.46 (95% CI 0.37; 0.55) (p<0.001) n=278). This means that for 
every 1 SD increase in log HOMA2IR, in men there was a 0.46 SD increase in circulating C3, while in women the 
increase was a 0.78 SD (crude associations). 
6.3.1. Additional analyses 
A more stringent cut-off value for alcohol consumption i.e. excluding all subjects who 
consumed >20 g/d of alcohol, has been proposed as a threshold to distinguish 
between non-alcoholic and alcoholic fatty liver disease [24]. We therefore repeated the 
analyses using this more stringent cut-off value. Again, a strong association was 
observed between HOMA2IR and C3 (n=381, β HOMA2IR was 0.56 (0.47; 0.64), 
p<0.001). When ALT was included in the full model, β for HOMA2IR decreased 
from 0.44 (0.30; 0.52) to 0.34 (0.24; 0.45)) which equals 16.1% mediation by ALT.  
It has been reported that plasma ALT levels may underestimate liver fat content in 
T2DM patients [30]. The analyses shown above were therefore also repeated without 
subjects with T2DM. When using the relaxed cut-off value for alcohol consumption, 
i.e. exclusion of women who consumed >20 g and men who consumed >40 g alcohol 
daily, the results were slightly attenuated compared to what was reported above; 
mediation by ALT was 8.8% (n=349). When using the more stringent cut-off value 
for alcohol consumption, i.e. exclusion of all subjects who consumed >20 g alcohol 
daily, mediation by ALT was 9.5% (n=290). 
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6.4. Discussion 
We investigated the mediating role of ALT -as a surrogate marker of fatty liver 
disease- in the association between insulin resistance (measured as HOMA2IR) and 
circulating concentrations of complement C3. Our results showed that after taking 
into account the effects of central obesity and low-grade inflammation and other risk 
factors, the strength of the association between insulin resistance and complement C3 
was indeed additionally attenuated by ALT.  
Insulin resistance and obesity-associated metabolic disorders are known to be 
associated with the amount of complement C3 in the circulation [6-9]. Our current 
data showed that the positive association between insulin resistance and C3 was 
independent of various metabolic and other risk factors. After adjustment for several 
covariates, including central obesity and inflammation, ALT attenuated the strength of 
this association by approximately 15%. Of note, our finding that mediation by ALT 
occurred while taking into account general low-grade inflammation using an 
inflammation score that included CRP, IL6, SAA, sICAM, ceruloplasmin and 
haptoglobin suggests that this mediation neither represented nor was a consequence 
of a general inflammatory / acute phase response that is often observed in NAFLD 
[31], but was specifically related to C3.  
The observed mediation suggests that fatty liver and concomitant liver dysfunction, as 
represented by ALT, may lead to an enhanced production of complement C3. 
Theoretically, increased amounts of circulating C3 may be due to either an increased 
production or to a decreased catabolism. However, C3 gene expression is increased in 
NASH [15], which is included in the NAFLD spectrum, and recent data suggest that, 
again in NASH, there is an increased rather than a decreased consumption of 
complement [32]. Therefore it is plausible that, in insulin resistance states, the 
production of C3 is increased to a level that (over)compensates for its consumption.  
There are several possible explanations for a mediating role of ALT. For instance, C3 
production may be induced by accumulation of intracellular triglycerides and their 
metabolites in the hepatocytes. In insulin resistance there is an increased flux of fatty 
acids from the adipose tissue to the liver [33]. Fatty acids are not only substrate for 
triglyceride synthesis, but also act as second messengers that induce gene-expression 
[34]. The same holds true for intermediates of triglyceride synthesis such as 
diacylglycerols [35]. On the other hand, NAFLD is also associated with compromised 
cellular metabolism including hypoxia and reduced mitochondrial function which may 
affect both the (hepatic) C3 expression and its consumption via complement 
activation [36-38], although this may to some extent reflect general expression of acute 
phase proteins, rather than being specific for C3.  
The final full model in this study explained approximately 40% of the association 
between insulin resistance and C3 (β for HOMA2IR was 0.55 in the crude association, 
compared to 0.34 in the full model), which leaves about 60% of this association 
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currently unexplained. This remaining association can be related to, for instance, 
additional intrahepatic processes that are not reflected by plasma levels of ALT or to 
contribution of additional extrahepatic sources such as the vascular endothelium to 
circulating C3, that are not represented by the currently included covariates. 
Alternatively, it may be related to a direct effect of insulin on (hepatic) C3 expression 
and synthesis, that is independent of the intermediate mechanisms considered. This is 
to some extent corroborated by data showing that the increase in C3 in response to an 
oral fat load is more pronounced in insulin resistant (i.e. those with the metabolic 
syndrome) than in insulin sensitive (no metabolic syndrome) subjects [6] and is 
blunted by an increased post-prandial insulin surge that was induced by addition of 
glucose to the fat load [13]. 
A strength of this study is the detailed phenotyping of low-grade inflammation in all 
subjects, which allowed us to calculate a robust inflammation score that comprised 
information on 6 individual inflammation markers. Potential limitations lie in the fact 
that we used ALT levels as a measure of hepatic fat accumulation. However, even 
though ALT levels are not the ideal measure of hepatic fat accumulation, they can 
represent an acceptable measure for NALFD in epidemiological studies [27,39] and 
we did observe significant mediation by ALT, independent of general inflammation. 
We are aware that ALT levels may be affected by various factors that were not 
measured in our population, such as specific dietary factors and physical condition 
[40-42]. However, the effects of such factors will most likely lead to greater (random) 
variation in the ALT data, which would make our current finding that ~14% of the 
association between insulin resistance and C3 is explained by ALT actually, if 
anything, more likely to be an underestimate of the true value. Other limitations may 
include that we measured total C3 concentration and not its activated compound C3a. 
However, it is the increased plasma concentration of C3 -rather than C3a- that has 
been identified as an important, independent risk factor for cardiovascular disease, 
hypertension and type 2 diabetes in cross-sectional as well as prospective studies [1-9], 
which was why we focused on complement C3 as the primary factor of interest in the 
current analyses. Lastly, the cross-sectional design of the study prohibits conclusions 
about causality, and the fact that the CODAM study population consists of middle-
aged Caucasian individuals with an increased T2DM and CHD risk profile may hinder 
direct extrapolation and to the general population. We did however adjust our analyses 
for potential confounders such as sex, smoking, presence of T2DM and CVD, use of 
medication, obesity and inflammation.  
In conclusion, approximately 15% of the association between insulin resistance and 
circulating complement C3 was mediated by ALT. The mediation by ALT may be 
primarily related to increased hepatic C3 production in NAFLD. 
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7.1. The CODAM Study 
The primary aims of the Cohort on Diabetes and Atherosclerosis Maastricht 
(CODAM) study are to evaluate the progression of atherosclerosis and cardiovascular 
disease (CVD) in subjects with a relatively high risk of type 2 diabetes mellitus 
(T2DM) and to evaluate the development of T2DM in subjects who were selected for 
specific T2DM risk factors. To be able to study these questions the cohort will be 
seen every 7 years to assure a regular follow-up. This thesis focused on the first 
primary aim. Since only the baseline measurements of this cohort were available by 
the time the investigations described in this thesis were done, data from cross-
sectional analyses are presented. 
7.2. The metabolic syndrome in CODAM 
Presence of the metabolic syndrome is a “common denominator” in subjects with 
high risk of CVD and T2DM [1-4]. The metabolic syndrome defines a clustering of 
risk factors including abdominal obesity, hypertension, elevated plasma triglyceride 
concentration, reduced high-density lipoprotein (HDL)-cholesterol concentration and 
elevated fasting blood glucose levels [5, 6]. Given the selection criteria for the 
CODAM study, the metabolic syndrome was likely to be a frequent finding in 
CODAM participants. Prevalence of the metabolic syndrome according to national 
cholesterol education program 2005 [7] was in subjects with normal glucose tolerance 
33.2%, with impaired glucose metabolism 69.3% and, with T2DM 86.3% in the 
CODAM participants. Cross-sectional and prospective studies have shown that the 
metabolic syndrome is associated with CVD and that people with the metabolic 
syndrome have an increased risk for future CVD [8-11]. However the exact 
mechanisms that might explain this association are not entirely clear. Therefore we 
investigated cross-sectionally which mechanisms/processes might underlie the 
association between the metabolic syndrome and CVD [12-14]. In these investigations 
we focused on several metabolic markers and potential intermediates that are of 
specific interest in the relation between the metabolic syndrome and CVD, including 
insulin resistance, inflammation, endothelial dysfunction, complement C3 and non-
alcoholic fatty liver disease (NAFLD).  
7.3. Central and peripheral artery disease in CODAM 
7.3.1. The metabolic syndrome and coronary and peripheral artery disease 
We first set out to investigate how the association between the metabolic syndrome 
and different aspects of cardiovascular disease were affected by intermediate processes 
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in CVD, i.e. inflammation and endothelial dysfunction. In these investigations we 
specifically focused on two distinct aspect of CVD i.e. the coronary and the peripheral 
vasculature, since these are two different vascular beds that might be affected in a 
different manner by the metabolic syndrome. 
We showed that low-grade inflammation explained, statistically, part of the association 
between the metabolic syndrome and coronary artery disease (CAD) (up to 26%) and 
the severity of peripheral artery disease (PAD) (up to 29%, Chapter 2). The most 
studied marker of systemic low-grade inflammation in association with the metabolic 
syndrome and CVD is C-reactive protein [15, 16]. However, more markers of 
inflammation exist, including interleukin 6, soluble intercellular adhesion molecules, 
soluble vascular cell adhesion molecules and serum amyloid A. These have been 
investigated before [15, 17-19], but only as separate markers. In our investigations we 
combined several inflammatory markers into a composed score that represented 
systemic low-grade inflammation what is a more robust measure for inflammation 
than the markers separately with the additional advantage of less misclassification [20]. 
Since the association between the metabolic syndrome and CAD and the severity of 
PAD was only partly explained by inflammation we subsequently investigated 
(Chapter 3) whether endothelial dysfunction could explain an additional part of this 
association. As a measure for endothelial dysfunction we also used a robust measure 
of biomarkers that were combined into an endothelial dysfunction score [20]. We 
found that endothelial dysfunction explained about 19% of the association between 
the metabolic syndrome and the severity of PAD, low-grade inflammation explained 
28%. Together endothelial dysfunction and low-grade inflammation explained 36%, 
so 8% was additional to low-grade inflammation (Figure 7.1). This implies that 
inflammation and endothelial dysfunction partly represent the same pathway in the 
relation between the metabolic syndrome and PAD but can have individual 
contributions as well. On the other hand, endothelial dysfunction did not explain any 
part of the association between the metabolic syndrome and CAD. Together with the 
former this shows that the pathogenesis of peripheral and coronary artery disease 
differ in this respect. It could be argued that it would have been better to use 
functional measure of endothelial dysfunction, like flow-mediated dilatation instead of 
biomarkers [21]. However compared to such a more direct measure of endothelial 
function, the use of biomarkers would only underestimate our findings which make 
our results unlikely to be a spurious finding.  
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Figure 7.1: The association between the metabolic syndrome and coronary artery disease (CAD) and 
peripheral artery disease (PAD), adjusted for age, sex and lifetime smoking, is partly mediated by 
inflammation (INFL) and endothelial dysfunction (ED) 
7.3.2. The complement system and coronary heart disease 
The complement factor C3 has been established as a cardiovascular risk factor in both 
cross-sectional and longitudinal studies [22, 23] and is substantially increased in the 
circulation of subjects with the metabolic syndrome [24].  
In the CODAM population (Chapter 4), we confirmed that human serum 
complement factor C3 was indeed cross-sectionally associated with coronary heart 
disease (CHD) as was previously shown by others [25-27]. However, based on 
previous in vitro data that cigarette smoke can activate the complement system by 
modifying complement C3 [28-30] we hypothesized that smoking may enhance the 
effect of complement of the risk of CVD. Indeed, closer examination of the 
association between complement C3 and CHD learned that this was mainly present in 
the group of heavy smokers. This association was independent of cardiometabolic risk 
factors like insulin resistance, systemic inflammation and the metabolic syndrome. The 
overall association of C3 with CHD we found in the whole CODAM population 
corresponds with the associations between C3 and prevalence of CHD, independent 
of age, sex and some additional risk factors reported by several other studies [23, 25, 
31, 32]. There are several possible explanations how smoking might increase the risk 
of CVD associated with C3 in these cross-sectional evaluations. A first explanation is 
that the activation of complement C3 by (heavy) smoking might be one of the 
mechanisms by which smoking can enhance the process of inflammation in the 
atherosclerotic plaque and thereby increasing the risk of CVD. Another possibility is 
that smoking would not directly affect the complement system but rather induce 
oxidative stress and inflammation in the atherosclerotic plaque, which might affect the 
expression and/or activation of the complement system. 
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7.4. Metabolic risk factors in CODAM 
7.4.1. The metabolic syndrome and non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease is a highly prevalent finding (70% to 80%) in subjects 
with the metabolic syndrome [33, 34] and has a wide histological spectrum ranging 
from simple steatosis and non-alcoholic steatohepatitis to more progressive forms 
such as fibrosis and eventually cirrhosis. Alanine aminotransferase (ALT) in the 
circulation is a simple measure for fatty liver disease. Several metabolic syndrome-
related processes might affect the development of NAFLD.  
We showed in Chapter 5 that insulin resistance was, statistically, the strongest 
mediator of the association between the metabolic syndrome and ALT while other 
metabolic syndrome related processes like inflammatory adipokines, endothelial 
dysfunction and non-esterified fatty acids (NEFA) also explained a part of the 
association, but to a lesser extent, Figure 7.2. The strong mediation by insulin 
resistance was not really surprising because of well-known relations between the 
metabolic syndrome, insulin resistance and steatosis [35]. The mediation by 
inflammatory adipokines and endothelial dysfunction did not add to the mediation by 
insulin resistance, which implies that these processes overlap and supports the notion 
that -in the metabolic syndrome- insulin resistance-associated adipose tissue 
inflammation and endothelial dysfunction might actually contribute to the 
development and/or progression of NAFLD, as reflected by ALT. NEFA on the 
other hand did add to the mediation by insulin resistance; about half of the mediation 
by NEFA was additional to insulin resistance. This suggests that half of the mediation 
by NEFA may occur via pathways included in the process of adipose tissue 
inflammation and insulin signaling, while the other half occurs via other processes like 
dietary fatty acids and direct uptake by hepatocytes of adipose tissue derived NEFA.  
 
 
Figure 7.2: The association between the metabolic syndrome and non-alcoholic fatty liver disease (NAFLD; 
measured as ALT), adjusted for age, sex, smoking, alcohol consumption and the use of lipid-lowering and 
anti-hypertensive medication, is for a very large part mediated by insulin resistance, with no independent 
contribution of adipose tissue inflammation, endothelial dysfunction. The mediation by non-esterified fatty 
acids (NEFA) is partly independent of insulin resistance 
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7.4.2. Fatty liver as an intermediate in the relation between insulin resistance 
and complement C3 
As described above (paragraph 7.3.2), increased levels of circulating complement C3 
are a frequent finding in subjects with the metabolic syndrome. Several aspects of the 
metabolic syndrome, including insulin resistance, may contribute to increased amounts 
of circulating complement factor C3.  
In the CODAM population, insulin resistance was, as expected based on literature [36, 
37], indeed associated with circulating concentrations of complement C3. We now 
showed that NAFLD, measured by ALT, partly explained this association, 
independent of obesity and low-grade inflammation (Chapter 6). Given the substantial 
production of C3 by the liver, the observed 14% mediation appeared, at first sight, to 
be quite low. However estimations of the contribution of the liver to systemic C3 are 
primarily based on data from subjects who received a liver transplantation [38] and 
such individuals can metabolically not be compared to the subjects in the CODAM 
study. Moreover, we did not study the association between ALT and circulating C3 
but evaluated to what extent ALT could explain the association between C3 and 
insulin resistance.  
 
Taking all the above together, our studies showed that several processes explain part 
of the association between the metabolic syndrome and (metabolic intermediates of) 
cardiovascular disease. These processes include low-grade inflammation, insulin 
resistance, endothelial dysfunction, complement and non-esterified fatty acids, but our 
investigations showed that these processes overall are partly overlapping and partly 
independent from each other.  
 
7.5. Methodological considerations 
7.5.1. Internal validity 
In the manuscripts presented in this thesis, we have used a range of biomarkers as 
proxy measures of general inflammation, adipose tissue inflammation and endothelial 
dysfunction. Different sets of markers were combined into scores to obtain more 
robust measures of these above-mentioned processes with the benefit of less 
misclassification and reduction of the problem of multiple testing. An important 
advantage of the use of biomarkers is that they are relatively easy obtainable in large 
epidemiological cohorts. A disadvantage might be that they are estimates of 
underlying (patho-)physiological processes but do not directly measure them. 
We have used several markers for low-grade inflammation and made a distinction 
between general and adipose tissue-related low-grade inflammation. C-reactive protein 
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is a marker for inflammation that is mostly produced by the liver and therefore a 
marker for general inflammation. Adiponectin and leptin on the other hand are 
markers that are exclusively produced by adipocytes and therefore representative for 
adipose-tissue related inflammation. The other markers we used (i.e. IL6, sICAM, 
SAA) are not unique produced in one cell type. So it is more difficult for these 
markers to assign them to a specific type of inflammation and therefore it is possible 
that both inflammation scores include markers that are not unique for that score. 
We also used biomarkers to estimate endothelial dysfunction. Functional measures for 
endothelial function have been used in other studies, however until now there is not a 
gold standard to measure endothelial dysfunction. The most used functional measure 
is endothelium-dependent flow-mediated vasodilatation. Unfortunately, this measure 
was not available. By using a combined score for endothelial dysfunction instead of 
one or more individual markers we, again, tried to reduce the problem of 
misclassification and multiple testing. 
The gold standard for diagnosing and staging NAFLD is a liver biopsy. This is an 
invasive procedure with risk of postinterventional bleeding and is therefore ethically 
not acceptable without clinical indication. Other techniques that are frequently used in 
epidemiological studies include imaging techniques like ultrasound or by measurement 
of circulating markers such as alanine-aminotransferase. However, previous studies 
have shown that ALT is a reasonable predictor of NAFLD as detected by ultrasound 
[39, 40]. 
Coronary artery disease was defined as self-reported myocardial infarction, bypass 
surgery of the coronary arteries, balloon dilatation or stent placement (through 
questionnaires) and/or the presence of signs of myocardial infarction or ischemia on a 
12-lead electrocardiogram. For more than 75% of the subjects, the self-reported CAD 
could be confirmed using available hospital registries. The ankle-arm index was 
measured for PAD, the most used method. Since only 28 of 574 subjects had an 
ankle-arm index (AAIx) < 0.9 (the traditional criterion to define PAD), we lacked 
power to use PAD as a categorical variable and we therefore used the AAIx as a 
continuous measure for the severity of PAD. 
7.5.2. External validity 
Subjects who were selected into CODAM had a relatively high risk of T2DM and 
CVD. Generalizability of our current data is therefore restricted to subjects who have 
a comparable risk profile of obesity, (slightly) disturbed glucose metabolism and/or 
high blood pressure. Subjects who fulfill these criteria are present in our Western 
society with a high prevalence and they are the ones who have the highest risk to 
develop cardiovascular and/or macrovascular complications. The data presented in 
this thesis can largely be generalized to those high-risk subjects and these data 
contribute to our understanding of development of disease in this particular group of 
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subjects. We should, however, be cautious with generalization of our results to high-
risk subjects of different ethnicity or of (much) younger age, since these were not 
included in our cohort.     
For more generalizable data, our investigations should be repeated in other 
populations. 
All studies presented in this thesis were done cross-sectionally which precludes 
conclusions on causality. 
7.6. Future research within CODAM 
From 2005 until 2009 all participants of the CODAM baseline measurement were 
invited to participate in the first follow-up evaluation (CODAM 2). Of the original 
574 participants, 491 (>85%) visited our laboratory twice for these 7 years follow-up 
evaluations. During these visits all measurements that were performed during 
CODAM 1 were repeated to assure that longitudinal analysis can be performed.  
During the first visit anthropometric measures were taken (length, weight, waist and 
hip circumference, skin-fold measures) and blood pressure was measured in both arms 
in sitting and in supine position. Besides in the arms, blood pressure was also 
measured in both legs, to be able to calculate the ankle-arm index. In supine position 
also an ECG was taken so signs of CAD could be recognized. Then fasting blood 
samples were taken to measure markers like among others glucose, HDL-cholesterol, 
triglycerides, markers of low-grade inflammation, complement C3 and endothelial 
dysfunction. To define whether the participants had T2DM we performed an oral 
glucose tolerance test, during which the participants completed the same 
questionnaires as were filled in during CODAM 1.  
The second visit was mainly used to perform vascular measurements and additional 
measurements on body composition and fat distribution. Ultrasound was used to 
measure intima-media thickness in both carotid arteries. Also the distension was 
measured in both carotid arteries as well as in the brachial and femoral arteries, as a 
measure of stiffness. Other measures of stiffness were the augmentation index and 
pulse wave velocity (central: carotid artery – femoral artery and peripheral: femoral 
artery – ankle). Since in CODAM 1 we only had the biomarker ALT as a measure for 
NAFLD, we now used ultrasound to have a more direct/better measure for fatty liver 
disease. Finally an intravenous glucose tolerance test was done.  
With the results of CODAM 2 together with those of CODAM 1, we will be able to 
study various aspects and causes of the development and progression of T2DM, 
atherosclerosis and CVD in these high-risk subjects.  
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Het metabool syndroom is een verschijnsel dat vaak voorkomt bij mensen met een 
hoog risico op type 2 diabetes mellitus en hart- en vaatziekten en is een cluster van 
risicofactoren, waaronder abdominale obesitas, hoge bloeddruk, verhoogde 
concentratie van triglyceriden en verlaagde concentratie van HDL-cholesterol in het 
bloed en verhoogde bloedglucose waardes. Als gevolg van de selectiecriteria die 
gebruikt zijn om te komen tot onze onderzoekspopulatie (Cohort Onderzoek naar 
Diabetes en Atherosclerose Maastricht; CODAM), werd het metabool syndroom vaak 
gevonden bij de deelnemers. Het metabool syndroom kwam bij 33.2% voor van de 
personen met een normale glucose tolerantie, bij 69.3% van de personen met een 
verminderde glucose tolerantie en 86.3% bij personen met type 2 diabetes. 
Diverse andere studies hebben al aangetoond dat het metabool syndroom 
geassocieerd is met hart- en vaatziekten en dat personen met het metabool syndroom 
ook een verhoogd risico hebben op hart- en vaatziekten in de toekomst. De precieze 
mechanismen die deze associatie kunnen verklaren zijn nog niet bekend. Daarom 
hebben wij gekeken naar de mechanismen/processen die hier aan ten grondslag 
kunnen liggen en hebben ons hierbij gefocust op insuline resistentie, ontsteking, 
endotheel dysfunctie, complement C3 en niet-alcoholische leververvetting. 
 
In hoofdstuk 2 en 3 hebben we gekeken naar de associatie  van het metabool 
syndroom met hart- en vaatziekten en hoe deze mogelijk verklaard kan worden. We 
hebben ons gefocussed op twee verschillende aspecten van hart- en vaatziekten, 
namelijk coronair vaatlijden en perifeer vaatlijden omdat deze twee vaatbedden 
waarschijnlijk op een andere manier door het metabool syndroom beïnvloed worden. 
We laten in hoofdstuk 2 zien dat laaggradige ontsteking statistisch gezien een deel kan 
verklaren van de associatie die gevonden is tussen het metabool syndroom en coronair 
vaatlijden (tot 26%) en van de associatie tussen het metabool syndroom en de ernst 
van perifeer vaatlijden (tot wel 29%). Diverse markers die in het bloed gemeten 
kunnen worden geven een maat voor laaggradige ontsteking, maar er is niet één 
marker die ‘uniek’ is. Daarom hebben we in ons onderzoek meerdere markers gebruikt 
voor het berekenen van een gecombineerde score die representatief is voor algehele 
laaggradige ontsteking. Deze score is een robuustere maat voor ontsteking dan de 
afzonderlijke markers met tevens het voordeel dat de kans op misclassificatie veel 
kleiner is. 
Aangezien laaggradige ontsteking de associatie tussen het metabool syndroom en 
verschillende aspecten van hart- en vaatziekten slechts voor een deel kan verklaren 
hebben we in hoofdstuk 3 gekeken of endotheel dysfunctie een extra deel van deze 
associatie kan verklaren. Voor endotheel dysfunctie hebben we, net als voor 
laaggradige ontsteking, een gecombineerde score berekend van diverse markers. 
Endotheel dysfunctie kon 19% en laaggradige ontsteking 28% van de associatie tussen 
het metabool syndroom en de ernst van perifeer vaatlijden verklaren. Samen 
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verklaarden ze 36%, dus endotheel dysfunctie voegde 8% toe aan de verklaring die 
gevonden werd door laaggradige ontsteking. Het lijkt er dus op dat laaggradige 
ontsteking en endotheel dysfunctie deels dezelfde route representeren, maar ook ieder 
hun eigen bijdrage hebben. Verder bleek dat endotheel dysfunctie niets verklaard van 
de associatie tussen het metabool syndroom en coronair vaatlijden. Dit laat, samen 
met het voorgaande, zien dat de pathogenese van perifeer en coronair vaatlijden 
verschillend is. 
 
In hoofdstuk 4 hebben we laten zien dat complement C3 cross-sectioneel 
geassocieerd is met coronair vaatlijden. Dit hebben we uitgebreider bekeken en zagen 
dat deze associatie voornamelijk naar voren kwam in de groep personen die veel 
rookt, onafhankelijk van cardiometabole risicofactoren zoals insuline resistentie, 
laaggradige ontsteking en het metabool syndroom. 
 
Niet-alcoholische leververvetting in verschillende gradaties wordt vaak gezien bij 
mensen met het metabool syndroom. Omdat leververvetting niet heel eenvoudig 
vastgesteld kan worden, hebben wij daarvoor de niveaus van alanine aminotransferase 
(ALT) in het bloed bepaald wat een vereenvoudigde maat is voor niet-alcoholische 
leververvetting. We laten in hoofdstuk 5 zien dat insuline resistentie de grootste 
verklaring gaf voor de associatie tussen het metabool syndroom en ALT. Andere 
processen die gerelateerd zijn aan het metabool syndroom verklaarden ook een deel 
van de associatie, maar waren niet zo sterk. Ontstekingsmarkers afkomstig uit 
vetcellen voegden niets toe aan de verklaring gevonden door insuline resistentie 
(77%), terwijl de helft van de verklaring door niet-geësterificeerde vetzuren (NEFA; 
5%) wel extra was bovenop insuline resistentie. Dit suggereert dat de helft van de 
mediatie door NEFA gebeurt volgens routes die samenvallen met processen als 
ontsteking in het vetweefsel en insuline signalering terwijl de andere helft gebeurt 
volgens andere processen. 
Eerder hebben we al laten zien dat een verhoogde concentratie van complement C3 in 
het bloed vaak gevonden wordt bij personen met het metabool syndroom. 
Verschillende aspecten van het metabool syndroom, inclusief insuline resistentie 
kunnen bijdragen aan verhoogde concentraties van C3 in het bloed. Insuline 
resistentie is geassocieerd met de concentratie C3 in het bloed in de CODAM 
populatie, zoals te zien is in hoofdstuk 6. We hebben tevens laten zien dat niet-
alcoholische leververvetting, gemeten als ALT, een deel van de associatie kan 
verklaren, onafhankelijk van obesitas en laaggradige ontsteking. 
 
Met alle bovenstaande bevindingen uit onze onderzoeken laten we zijn dat diverse 
processen een deel kunnen verklaren van de associatie tussen het metabool syndroom 
en (metabole intermediairen van) cardiovasculaire ziektes. Met de processen bedoelen 
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we laaggradige ontsteking, insuline resistentie, endotheel dysfunctie, complement en 
niet-geësterificeerde vetzuren. Verder hebben we laten zien dat deze processen deels 
overlappend zijn en deels onafhankelijk van elkaar. 
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Eindelijk, het is zover! Het dankwoord kan geschreven worden na vier jaar full-time 
onderzoek en anderhalf jaar alles afronden in eigen tijd. Misschien verbaast het mezelf 
nog wel het meest dat het zover gekomen is. Het tot stand komen van dit proefschrift 
was nooit gelukt zonder de hulp en steun van heel veel mensen. 
 
Als eerste wil ik alle proefpersonen van CODAM bedanken: iedereen die de stap heeft 
genomen om alle onderzoeken te ondergaan ten tijde van CODAM 1 (1999-2001) en 
speciaal iedereen die het aandurfde om in de periode 2006-2009 nog een keer terug te 
komen om twee ochtenden nuchter allerlei onderzoeken te ondergaan voor CODAM 
2. Het praktische werk maakte voor mij het promoveren leuk omdat ik met mensen 
kon werken, verschillende (levens-)verhalen hoorde en niet alleen maar ‘achter de 
computer’ hoefde te zitten. 
 
Daarna is mijn promotieteam aan de beurt om bedankt te worden. Promotor Prof. Dr. 
Stehouwer, beste Coen, bedankt voor al je hulp bij mijn promotie, het lezen van alle 
artikelen en de opmerkingen die er voor zorgden dat het betere manuscripten werden. 
Ook wil ik je bedanken voor je steun. In het eerste jaar kwam het bericht dat de 
externe financiering weg zou vallen en jouw eerste reactie was dat in ieder geval mijn 
promotietraject veilig was en door moest gaan. Daarvoor ben ik je zeer dankbaar. 
Marleen en Carla, mijn co-promotores, ook jullie ben ik veel dank verschuldigd. Jullie 
hebben mij intensief geholpen om CODAM 2 en ook dit proefschrift tot een succes te 
brengen. De deur stond altijd open voor al mijn vragen en ook jullie hadden er geen 
moeite mee om proefpersoon te zijn als er weer eens metingen geoefend moesten 
worden.  
 
Isabel, je was altijd weer bereidt om een geschreven paper te lezen en van het nodige 
commentaar te voorzien. Het was niet altijd even leuk om ze van je terug te krijgen, 
maar de kwaliteit verbeterde er wel door. Verder heb je in het begin veel geholpen 
door mij te leren hoe ik vaatecho’s moet maken, een belangrijk onderdeel van 
CODAM 2. 
 
CODAM 2 is zo succesvol verlopen dankzij de hulp die ik van velen gekregen heb.  
Josephine, jij hebt echt een engelengeduld! De tijd die jij erin gestopt hebt om alle 
proefpersonen te bellen en te overtuigen om weer aan de onderzoeken mee te doen. 
Geweldig, zonder jou waren het er veel minder geweest. Dany, ook zonder jouw hulp 
hadden we niet zo veel personen kunnen includeren. Jij hebt veel voorbereidingswerk 
gedaan (o.a. stickeren van buisjes) en ook vele metingen heb jij voor je rekening 
genomen. Eigenlijk moet ik hier iedereen van het lab bedanken, omdat iedereen wel 
iets heeft gedaan. Vicky en Margee bedankt voor al het pipetteren; Johanna, Lian en 
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Roel bedankt voor jullie hulp bij de visites/metingen; Petra en Marjo, bedankt voor 
het (ont)stickeren van buisjes. Verder is iedereen van de afdeling wel eens of meerdere 
keren proefpersoon geweest, voor het oefenen en valideren van alle metingen. 
Het maken van buikecho’s heb jij, Martijn, mij geleerd, dank daarvoor en Frans 
bedankt voor het beoordelen van de leverecho’s. Jos bedankt voor het helpen bij het 
maken de buikecho’s en de IVGTT’s en Arne bedankt voor het beoordelen van de 
ECG’s. Jeroen bedankt voor het regelen van de onderzoeksruimte en de houder die ik 
gebruikte bij de vaatecho’s.  
Natuurlijk zijn ook de studenten die hun wetenschappelijke stage bij CODAM hebben 
gedaan belangrijk: Petra, Mieke, Jesse en Mirjam, bedankt voor jullie hulp. En ook de 
studenten die vele buisjes bloed gepipetteerd hebben, bedankt. 
 
Dan mijn oud-kamergenoten. Steven, we hebben niet heel lang samen op één kamer 
gezeten, omdat jouw promotie zich in de afrondende fase bevond, maar het was wel 
een leuke tijd. Katrien we zijn tegelijk begonnen aan onze promotie en Olaf jij ruim 
een half jaar later. Het waren onderzoeken met verschillende onderwerpen, maar toch 
kon er genoeg gediscussieerd worden en waren er zeker ook genoeg gezellige 
gesprekken. Jullie hebben jullie promotie inmiddels allebei al afgerond, super! Veel 
succes met jullie post-doc onderzoeken. Bas, jij bracht nog een nieuw onderwerp in de 
kamer: voeding. Al snel was je aangepast en discussieerde en kletste je gezellig mee in 
de kamer. Succes verder met jouw promotie, dit geldt ook voor Johanna, Lian, Roel, 
Marcelle en Nordin.  
 
Ook mijn huidige (oud-)kamergenoten/collega’s van de afdeling O&I van de Inspectie 
voor de Gezondheidszorg wil ik bedanken voor de interesse die jullie regelmatig 
toonden in de afronding van mijn promotie.  
 
Tijdens een onderzoeksperiode is ook ontspanning heel erg belangrijk. Ellen, Karin, 
Anke en Karolien bedankt voor de regelmatige ontzettend gezellige etentjes, uitjes, 
verjaardagsfeestjes en dergelijke, die zorgden voor een welkome afwisseling. Ellen, 
nadat je zelf al gepromoveerd bent, mag je nu ook nog meemaken hoe het is om 
paranimf te zijn. Echt heel leuk dat je deze taak op je wilt nemen. Ook het jaarlijkse 
ME-weekendje met Karin, Ellen, Cathryn, Karolien, Michiel, Ruud, Anne, Vera, Maud 
en natuurlijk Egon waren een zeer welkome afwisseling. Helaas kunnen Egon en ik dit 
jaar zeer waarschijnlijk niet mee, maar volgend jaar zijn we zeker weer van de partij! 
 
Suus en Roy, lieve zus en (schoon)broer, ook jullie hebben voor veel steun, 
ontspanning en plezier gezorgd. Twee keer per week gingen we gedurende die vier jaar 
promotieonderzoek samen sporten en konden we gezellig bijkletsen. Afleiding kwam 
ook door de komst van mijn lieve nichtje Milou en neefje Chris, die er voor zorgden 
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dat ik nog vaker bij jullie over de vloer kom. Suus, bedankt dat je mij ook vandaag wilt 
steunen door mijn paranimf te zijn. 
 
Pap en mam, bedankt voor alles, voor jullie steun, jullie hulp en jullie vertrouwen. 
Jullie stonden en staan nog steeds altijd voor me klaar en dat is een heerlijk gevoel. En 
het motto: “het komt allemaal goed”, houden we er in. 
 
Egon, we hebben uitgerekend hoeveel kilometers we hebben moeten reizen om 
tijdens mijn promotietijd in de weekenden bij elkaar te kunnen zijn: 70592 km, oftewel 
1.76 keer de aarde rond! Maar het is zeker wel de moeite waard geweest. De 
weekenden samen zorgden voor de nodige ontspanning in mijn “buitenhuisje” in 
Amsterdam of in jouw “buitenhuisje” in Meijel. Ook kon ik je bellen als ik weer eens 
even mijn verhaal kwijt moest. Je was er dag en nacht om me te steunen. Super fijn dat 
je me geholpen hebt met de laatste zware loodjes van dit proefschrift en nu op naar 
ons eigen huis, waar we hopelijk snel de sleutel van krijgen en samen heel veel jaren 
kunnen wonen. 
 
Marjon 
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Marjon Jacobs werd op 12 augustus 1982 geboren in Meijel. Het VWO diploma 
behaalde zij in 2000 aan het Bouwens van der Boye College te Panningen, waarna zij 
begon aan de Bachelor Biomedische Technologie aan de Technische Universiteit 
Eindhoven waarvan het diploma werd behaald in 2004. De daarop volgende de 
Master Medical Engineering die werd verzorgd door de Technische Universiteit 
Eindhoven in combinatie met het Academisch Ziekenhuis Maastricht / Universiteit 
Maastricht. Een stage werd afgerond op de afdeling radiologie en het 
afstudeeronderzoek werd verricht bij het radiotherapeutisch instituut MAASTRO 
waarvan ze de resultaten mocht presenteren op het ESTRO congres te Lissabon en 
later ook werden gepubliceerd. In de zomer van 2005 behaalde ze het Masterdiploma. 
Vanaf januari 2006 werkte zij gedurende vier jaar aan haar promotieonderzoek bij het 
laboratorium voor metabolisme en vasculaire geneeskunde van de Universiteit 
Maastricht, waarvan de resultaten zijn beschreven in dit proefschrift. Gedurende haar 
onderzoeksperiode bezocht zij congressen over diabetes in Amsterdam (Nederland), 
Rome (Italië) en Wenen (Oostenrijk). Sinds april 2010 werkt zij als stafmedewerker op 
de afdeling Onderzoek en Innovatie van de Inspectie voor de Gezondheidszorg. 
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AAIx   ankle-arm index 
AHA   American Health Association 
ALT   alanine aminotransferase 
CAD   coronary artery disease 
CHD   coronary heart disease 
CODAM  Cohort on Diabetes and Atherosclerosis Maastricht 
CRP   C-reactive protein 
CVD   cardiovascular disease 
ECG   electrocardiogram 
EGIR   European Group for Study of Insulin Resistance 
HDL   high-density lipoprotein 
ICAM   intercellular adhesion molecule 
IDF   International Diabetes Federation 
IFG   impaired fasting glucose 
IGM   impaired glucose metabolism 
IGT   impaired glucose tolerance 
IL   interleukin 
IRS   insulin receptor substrate 
LDL   low-density lipoprotein 
MCP   monocyte chemoattractant protein 
NAFLD  non-alcoholic fatty liver disease 
NCEP-ATP III National Cholesterol Education Program Adult Treatment 
Panel III 
NEFA   non-esterified fatty acids 
NGT   normal glucose tolerance 
NHLBI   National Heart Lung and Blood Institute 
OGTT   oral glucose tolerance test 
PAD   peripheral arterial disease 
PAI   plasminogen activator inhibitor 
PKC   protein kinase C 
SAA   serum amyloid A 
T2DM   type 2 diabetes mellitus 
TNFα   tumour necrosis factor α 
VCAM   vascular cell adhesion molecule 
VLDL   very-low-density lipoprotein 
vWF   von Willebrand factor 
WHO   World Health Organisation 

  
